

CURRICULUM VITAE

DANIEL A. BAROCAS, M.D., M.P.H., F.A.C.S.

Office Address: Vanderbilt University Medical School
Department of Urologic Surgery
A-1302, Medical Center North
Nashville, Tennessee 37232-2765
Phone (615) 343-2036
Fax (615) 322-8990
dan.barocas@vanderbilt.edu

Education:

College: University of Pennsylvania, College of Arts & Sciences
September 1988-May 1992
B.A., Cum Laude in Psychology, May 1992

University of Pennsylvania, Wharton School
September 1988-May 1992
B.S.E., Cum Laude in Management, May 1992

Pre-medical: CUNY Brooklyn College, Post-baccalaureate pre-med program
February 1995-December 1996

Medical School: Johns Hopkins University School of Medicine
September 1997-May 2001
M.D., May 2001

Public Health: Vanderbilt University School of Medicine
July 2008-May 2010
M.P.H., May 2010

Postgraduate Training:

Surgery Residency: New York Presbyterian Hospital-Weill Cornell Medical Center
New York, NY
June 2001-June 2003

Urology Residency: New York Presbyterian Hospital-Weill Cornell Medical Center
New York, NY
July 2003-June 2007

Fellowship: Fellow in Urologic Oncology and Minimally Invasive Oncology
Vanderbilt University Medical Center
Department of Urologic Surgery
Nashville, TN

July 2007-June 2009

Medical Licensure:

New York State, (expired) #228182
April 23, 2003 – April 29, 2008

Tennessee, (active)
April 2007 – April 2009 #42097
Renewed April 30, 2010, 2012, 2014-
2016

Georgia, (active) #062813
April 30, 2009 – April 30, 2011
Renewed April 30, 2013, April 30 2015

Certification:

American Board of Urology -
February 28, 2011 – February 28, 2021

Hospital Appointments:

Department of Veterans' Affairs Medical Center
Clinical Staff
Nashville, TN
July 2007 to present

Nashville Metropolitan General Hospital
Clinical Staff
Nashville, TN
July 2007 to present

Vanderbilt University Medical Center
Department of Urologic Surgery
Clinical Instructor
July 2007 to December 2009

Vanderbilt University Medical Center
Department of Urologic Surgery
Assistant Professor
January 2010 to December 2015

Vanderbilt University Medical Center
Department of Urologic Surgery
Associate Professor
January 2016 to present

Professional Positions:

Manager of Operations
Action Restorers Building Restoration Company
May 1992-June 1994

Volunteer Research Assistant
New York Presbyterian Hospital-Weill Cornell Medical Center
Department of Psychiatry
June 1994-January 1995

Project Coordinator of NIH-funded study of posttraumatic stress disorder
New York Presbyterian Hospital-Weill Cornell Medical Center
Department of Psychiatry
February 1995-June 1997

Laboratory Technician in wound-healing laboratory
New York Presbyterian Hospital-Weill Cornell Medical Center
Department of Surgery
January 1997-June 1997

Professional Organizations:

American Urological Association

Hematuria Guideline Panel Member, 2009

Abstract reviewer and conference session moderator, 2012-Present

Course faculty for "Prostate Cancer Diagnosis: PSA and Beyond", 2012 to present

Chair of Genitourinary Cancer Quality Measure Development Committee for ACS Commission on Cancer, AUA and SUO, 2013-Present

Member of Quality Measure Development Committee for AUA and NSQIP, 2014-Present

AUA Leadership Program 2014-15

Editorial Board 2014-Present

Quality Improvement Patient Safety Committee 2014-Present

Course faculty for "Evaluation and Management of Urinary Tract Bleeding", 2015

Liaison to the Commission on Cancer 2015-2018

Southeastern Section American Urological Association

Member 2008-Present

Abstract reviewer and conference session moderator 2012-Present

National Comprehensive Care Network

Prostate Cancer Early Detection Guideline Panel Member 2010-2015

Society of Urologic Oncology

Young Urologic Oncologists executive committee member 2009-2014

Young Urologic Oncologists executive committee president
2014-Present

Commission on Cancer
American Urological Association Liaison 2015-18
Quality Integration Committee Member 2015-Present

American Joint Committee on Cancer (AJCC) Staging Manual
Genitourinary Cancers Committee Member, 2011 to present

American College of Surgeons
Abstract reviewer and conference session moderator 2012-
Present
Fellow 2013-Present

Vanderbilt Urology Society
Secretary 2014-16

Movember Foundation Global Prostate Cancer Health Outcomes
Network
International advisory board, 2015-Present

Elliot Newman Society – Organization for physician-scientists at
Vanderbilt University with career development funding, 2009-Present

Professional Activities:

Intramural

Vanderbilt University Master in Public Health Curriculum Committee,
2009-14

Medical Director of 9S Inpatient Urologic Surgery Unit, 2012 to present

Senior Research Mentor and Course development committee member
for second year medical student research curriculum, 2013 to 2015

Member of the Care Model Steering Committee, representing the
Section of Surgical Sciences – Strategizing with senior hospital
leadership to help Vanderbilt adjust to value-based healthcare within
the Vanderbilt Health Affiliated Network, 2014 to present

Extramural

Editorial Work

Assistant Editor: *Journal of Urology* 2014-Present

Reviewer: *Medical Care*

Cancer

Journal of Clinical Oncology

JAMA Surgery

Urology Practice

Annals of Surgical Oncology

Urology

British Journal of Urology International

Prostate Cancer and Prostatic Diseases

Urologic Oncology: Seminars and Original Investigations

AUA Educational Materials

Agency for Healthcare Research and Quality Evidence Reviews

Awards:

Murphy Luncheon Attendee,
American Urological Association Annual Meeting, 2006

Second Prize, Valentine Essay Contest,
New York Academy of Medicine, Urology Section, 2006

TAP CaPSURE Scholarship, 2006-2007

ASCO Foundation Merit Award 2007

Murphy Luncheon Attendee,
American Urological Association Annual Meeting, 2007

ASCO Foundation Merit Award 2008

Best Reviewer of Manuscripts in Bladder and Kidney Cancer,
Journal of Urology, 2008

Best Reviewer of Manuscripts in Prostate Cancer,
Journal of Urology, 2010

Study Sections:

Prostate Cancer Foundation of Australia 2011

Department of Defense Congressionally Directed Medical Research Programs in Prostate Cancer, 2012, 2013

National Cancer Institute Special Emphasis Panel (Review of Program Project [P01] Applications) 2014, 2015

International Activities:

Expert Advisory Panel Member for study entitled "Systematic review and economic modeling of the relative clinical benefit and cost-effectiveness of laparoscopic and tele-robotic methods for surgical removal of the prostate in men with localised prostate cancer in the United Kingdom," funded by the National Institute of Health Research, Health Technology Assessment Programme, 2010-2011

International Scientific Board Member for Spanish Journal, Archivos Espanoles de Urologia, 2011 to present

Invited Speakerships:

Moderator of Cornell Athermal Robotic Technique Demonstration at The Advanced Robotic Techniques (ART) of Prostatectomy Symposium, New York, August 2006

Moderator of Live Robotic Radical Prostatectomy at the Satellite Symposium of the American Urological Association Annual Meeting, May 2007

"Surveillance for low-risk prostate cancer." Rhamey-Shelly Visiting Professorship Lecture, Nashville, TN, November 2007

Moderator of Live Robotic Radical Prostatectomy at the Satellite Symposium of the American Urological Association Annual Meeting, May 2008

"Screening and other controversies in prostate cancer." Community outreach lecture in Macon County, TN, February 2009

"Active Surveillance for Management of Low-Risk Prostate Cancer." PCA-3 Symposium in Dallas, TX, February 2009

"Oxidative Stress and Prostate Carcinogenesis." New York University Department of Urology Grand Rounds, March 2009

Moderator of Live Robotic Radical Prostatectomy at the Satellite Symposium of the American Urological Association Annual Meeting, May 2009

Moderator of Podium Session Bladder Cancer: Superficial (II) at the 2009 American Urological Association Annual Meeting, April 2009

“Schistosomiasis control and the changing epidemiology of bladder cancer in Egypt.” Vanderbilt Institute for Global Health, August 2009

“Schistosomiasis control and the changing epidemiology of bladder cancer in Egypt.” Rhamey-Shelly Visiting Professorship Lecture, Nashville, TN, October 2009

Moderator of Live Robotic Radical Prostatectomy at the Satellite Symposium of the American Urological Association Annual Meeting, May 2010

“Racial variation in the quality of care for prostate cancer.” Rhamey-Shelly Visiting Professorship Lecture, Nashville, TN, October, 2010

Moderator of Prostate Cancer Session at the Southeastern Section American Urological Association Annual Meeting, New Orleans, LA March 2011

“Best evidence in radical prostatectomy for prostate cancer.” Confederacion Americana de Urologia Meeting at the American Urological Association Annual Meeting, May 2011

“The Volume-Outcome Relationship in Urologic Oncology.” Rhamey-Shelly Visiting Professorship Lecture, Nashville, TN, October, 2011

Moderator of a Panel Discussion on Comparative Effectiveness Research in Urologic Oncology. Society of Urologic Oncology annual meeting, Bethesda, MD, December 2011

“Controversies in Prostate Cancer Screening.” Plenary Session at the Southeastern Section of the American Urological Association, Amelia Island, FL, March 2012

Co-Moderator of Urology and Reproductive Surgery session. American College of Surgeons Clinical Congress, Chicago, IL, October 2012

“Current and Future Role of Surgery in the Treatment of Prostate Cancer.” American College of Surgeons Clinical Congress, Chicago, IL, October 2012

“Physician-Led Quality Improvement in Urology.” Rhamey-Shelley Visiting Professorship Lecture, Nashville, TN, October, 2012

“Prostate Cancer Screening. All or None... or Some?” General Internal Medicine Grand Rounds, Vanderbilt University, Nashville, TN, March 2013

“Update on Prostate Cancer Screening.” American College of Surgeons Clinical Congress, Washington, D.C., October 2013

“Quality of Care for the Evaluation of Hematuria.” Rhamy-Shelley Visiting Professorship Lecture, Nashville, TN, October, 2013

“Evaluation of Hematuria.” General Internal Medicine Grand Rounds, Vanderbilt University, Nashville, TN, September, 2014

“What is the Best Treatment for Localized Prostate Cancer?” Rhamy-Shelley Visiting Professorship Lecture, Nashville, TN, November, 2014

“The Role of PSA in Prostate Cancer Detection.” Winter Urologic Forum, Vail, CO, January 2015

“MRI for Prostate Cancer Diagnosis.” Winter Urologic Forum, Vail, CO, January 2015

“Evaluation of Patients with Hematuria.” Winter Urologic Forum, Vail, CO, January 2015

“Value-Based Care: The elusive relationship between quality measures and patient-centered outcomes.” Surgical Outcomes Club didactic webinar, June 2015

“Surgeon’s Perspective on Surgical Quality and Outcomes Research.” INFORMS Healthcare Conference, Nashville, TN, July 2015. Organizer of 2-hour session, and lecturer

“The effect of the United States Preventive Services Task Force grade D recommendation against screening for prostate cancer on incident prostate cancer diagnoses in the US.” Prostate Health Education Network Annual Disparities Summit, Washington, DC, September 2015

“Value-Based Care: The elusive relationship between quality measures and patient-centered outcomes.” Section of Surgical Sciences Research Conference, Vanderbilt University Medical Center, September 2015

“Update on Screening for Prostate Cancer.” University of Tennessee Cancer Center Annual ‘Big 4’ Conference, Knoxville, TN, October 2015

“Rhamy Shelley Visiting Professorship.” Nashville, TN, October 2015. Organizer of 2-day conference

Teaching Activities:

Second-Year Medical Student Clinical Research Course:

Collaborated in development of curriculum and course content

Senior Research Mentor and Lecturer for second-year students

LECTURES:

House Staff Education Conferences

Screening for prostate cancer, February 2009
Treatment of localized prostate cancer, February 2009
Screening for prostate cancer, January 2010
Statistics and epidemiology, April 2010
Bladder cancer detection, April 2012
Statistics and epidemiology (2 lectures), March 2013
Statistics and study design (2 lectures), March 2015

Other Educational Talks

Men's Health Lecture to Vanderbilt Undergraduates to kick off the Movember fund-raiser, November 2010
Complexity of PSA and Its Use in Prostate Cancer Screening, Seminar for Epidemiology Doctoral students, 2011
Complexity of PSA and Its Use in Prostate Cancer Screening, Seminar for Epidemiology Doctoral students, 2012

Clinical Teaching:

Supervision of residents, fellows and faculty in urologic oncology and robotic surgery 2007-Present. Clinic (1 day per week); Operating room (2 days per week)

Research Supervision:

Medical Students:

Sanjay Patel

Research elective in Urologic Oncology 2007-2008
Research project: 1) Prediction of occult bladder cancer in the prostate at the time of cystectomy (manuscript published)
Current position: Urologic Oncology Fellow at University of Chicago

Mark Newton

Research elective in Urologic Oncology 2008-2009
Research project: Relationship of prostate volume and tumor grade in prostatectomy specimens. (Manuscript published)
Current position: Urology resident at University of Iowa

Monty Aghazadeh

Research elective in Urologic Oncology 2009-2010
Research project: 1) The impact of prostate volume on the likelihood of prostate cancer upgrading. (Manuscript published) 2) Discharge status after cystectomy. (Manuscript published)
Current position: Urology resident at Baylor College of Medicine, TX

Justin Gregg

Research elective in Urologic Oncology 2010-2011

Research project: The impact of preoperative nutritional status on outcome of radical cystectomy for bladder cancer. (Manuscript published)

Current position: Urology resident at Vanderbilt

Stephen Kappa

Research elective in Urologic Oncology 2010-2012

Research projects: 1) Cost comparison of open vs. robotic cystectomy (Poster presented); 2) Blood loss and transfusion in open vs. robotic cystectomy (Poster presented); 3) Benchmarking use of appropriate processes of care for cystectomy at Vanderbilt

Current position: Urology resident at Vanderbilt

Jacob Ark

Research elective in Urologic Oncology 2011-2012

Research projects: 1) Prostate biopsy related infections – assessment and improvement of the antibiotic prophylaxis protocol (Poster presented); 2) Upstaging at cystectomy in cT1 bladder cancer (Poster presented, manuscript published)

Current position: Urology resident at Vanderbilt

Alexandra May

Research elective in Urologic Oncology 2012

Research project: 1) Open vs. robotic prostatectomy for intermediate- and high-risk prostate cancer (Poster accepted, manuscript submitted)

Current position: Medical student at Vanderbilt

Chirag Kulhali

Research elective in Urology 2012

Research project: Bench-marking use of rapid response by surgical services at a tertiary care hospital (Poster presented, manuscript published in JACS)

Current position: Medical student at Vanderbilt

David Moore

Research elective in Urology 2012

Research project: 1) Recurrence and use of adjuvant therapy in men with pT3 prostate cancer (Poster submitted)

Current position: Urology resident at Vanderbilt

David Friedlander

Research elective in Urology 2012

Research project: 1) Variation in the evaluation of hematuria in primary care patients (Poster submitted)

Current position: Urology resident at Brigham and Women's Hospital

Carolyn Lai

Research elective in Urology 2014

Research project: Infections after office cystoscopy in the transplant population and general population. (Poster presented; manuscript submitted.)

Maximillian Lang

Research Immersion in Urology 2015

Research project: Use of natural language processing to extract data regarding quality measure compliance from the medical chart.

Current position: Medical student at Vanderbilt

Residents:

Christopher Anderson

Research rotation 2010-2012

Research projects: 1) Spurious elevation of PSA (manuscript published); 2) Centralization of prostatectomy and the role of robotic surgery (manuscript published); 3) Quality of cystectomy in women with bladder cancer (in progress)

Current position: Urologic Oncology Attending at Columbia University

Sanjay Patel

Research rotation 2010-2011

Research project: Dissemination of partial nephrectomy in the US (manuscript published)

Current position: Urologic Oncology Attending at Oklahoma University

Cary J. Stimson, Jr.

Research rotation 2012

Research project: Sociodemographic variation in use of appropriate processes of care for patients with muscle-invasive bladder cancer (manuscript published)

Current position: Urology resident at Vanderbilt

Shreyas Joshi

2014-15

Research rotation

Research project: Race as a predictor of participatory decision making in prostate cancer treatment decisions. (in progress)

Justin Gregg

Research rotation

Research projects: 1) Use of natural language processing to extract data regarding quality measure compliance from the medical chart. 2)

Infections after office cystoscopy in the transplant population and general population.

Fellows:

Shady Salem, Research Fellow

2008-2009

Research projects: 1) Prostate cancer tumor volume as a predictor of biochemical recurrence. (Manuscript published) 2) Comparison of

pathologic findings in whole mount versus systematic sectioning of prostatectomy specimens. (Manuscript published) 3) Schistosomiasis and bladder cancer in Egypt (Manuscript published)
Current position: Urologist in Egypt

Yakup Kordan, Research Fellow 2008-2009
Research projects: 1) Prognostic significance of pathologic T2 sub-stages of prostate cancer (Manuscript published); 2) Prognostic significance of positive apical margins in prostate cancer. (Manuscript published); 3) Transfusion rates in robotic vs. open prostatectomy (Manuscript published)
Current position: Urologist in Turkey

Kirk (Pat) Keegan, Fellow in Urologic Oncology
MPH Thesis, Research year 2010-2012
Research projects: Changing use of neoadjuvant and adjuvant chemotherapy for bladder cancer (Poster presented)
Current position: Staff urologist at Brooke Army Medical Center

Jeffrey Bassett, Fellow in Urologic Oncology
Research year 2013-2014
Research project: Race differences in the evaluation of hematuria among Medicare recipients as a possible explanation for differences in stage at presentation of bladder cancer (published).

Chad Ritch, Fellow in Urologic Oncology
Research year 2013-2014
Research project: The transition from watchful waiting to active surveillance for prostate cancer: evidence from SEER-Medicare 1995-2007 (published).

William Sohn, Fellow in Urologic Oncology
Research year 2014-2015
Research project: Validation of quality measures for prostate cancer care (manuscript submitted).

John Eifler, Fellow in Urologic Oncology
Research year 2014-2015
Research project: Active surveillance for prostate cancer in the 1990s and 2010s (manuscript submitted).

Junior Faculty:

Oliver Gunter, Assistant Professor in Emergency General Surgery
MPH Thesis 2013-2014
Research project: Quality of care for emergency surgical conditions of the large and small bowel: the role of hospital teaching status in complications and mortality

Research Program:

Current Support

1R01 CA155388-01A1 Parikh (PI) July 2011-April 2016
NIH/NCI

Open vs. Robot-Assisted Radical Cystectomy: A Randomized Trial

The primary goal of this multi-center randomized controlled trial is to compare the effectiveness of these two approaches to radical cystectomy with respect to cancer control outcomes.

Role: Site PI; 2% effort and salary support

1R01HS022640-01 Penson (PI) September 2013-August 2018
AHRQ

Comparative Effectiveness of Modern Therapies for Localized Prostate Cancer

The primary goal of this study is to compare the effectiveness of surgery vs. radiation for management of localized prostate cancer. We will collect and assess 5-year quality of life outcomes among men in a large, population-based cohort.

Role: Co-investigator; 5% effort and salary support

1R03CA173807-01 Barocas (PI) January 2013-December 2014
NCI (NCE through June 2015)

The Quality of Care in Evaluating Patients Suspected of Having Bladder Cancer

The proposed study aims to identify gaps in the timely and complete evaluation of hematuria in two distinct datasets covering broad segments of the population, in order to develop targets for interventional studies aimed at improving the quality of care of these patients.

Role: PI; 5% effort, with salary support

1R03CA173812-01 Barocas (PI) January 2013-December 2014
NCI (NCE through June 2015)

Trends in Surveillance for Localized Prostate Cancer and Barriers to its Use

Surveillance strategies for men with low-risk prostate cancer have proven successful, but their adoption seems to be quite limited. The proposed study will link two population-based prospective cohort studies (one from the 1990's and the other from the 2010's), in order to identify some of the barriers to widespread use of surveillance, and, in doing so, to provide targets for a planned intervention study, designed to increase use of surveillance in appropriate clinical scenarios.

Role: PI; 5% effort, with salary support

CE-12-11-4667 Penson (PI) September 2013-August 2016
PCORI

Comparative Effectiveness of Treatments for Localized Prostate Cancer (CEASAR)

The primary goal of this study is to compare the effectiveness of surgery vs. radiation for management of localized prostate cancer. We will collect and assess 3-year quality of life outcomes among men in a large, population-based cohort.

Role: Co-investigator; 5% effort and salary support

Previous Research Support:

Grant #415a Barocas (PI) Nov 2008-Nov 2009
Vanderbilt Institute for Clinical and Translational Research
Outcomes of robotic-assisted laparoscopic prostatectomy vs. radical retropubic prostatectomy
This was a cohort study to compare cancer control outcomes between two surgical approaches to radical prostatectomy for prostate cancer.
Role: PI
Amount: \$1000

Grant: #410a Barocas (PI) October 2008-October 2009
Vanderbilt Institute for Clinical and Translational Research
Use of prostate size to predict high-grade prostate cancer
This study was designed to determine the value of prostate size in predicting the presence of high-grade prostate cancer
Role: PI
Amount: \$1000

Grant: #415b Barocas (PI) Nov 2008-Nov 2009
Vanderbilt Institute for Clinical and Translational Research
Pathologic findings and outcomes in pT2 prostate cancer with positive margins
The primary goal of this study was to determine whether positive margins in otherwise organ-confined prostate cancer are associated with inferior outcomes compared to negative margins.
Role: PI
Amount: \$2000

Grant #525 Barocas (PI) February 2009-January 2010
Vanderbilt Institute for Clinical and Translational Research
Comparison of pathologic processing methods in radical prostatectomy specimens
This was a retrospective cohort study to compare a more resource-intensive pathologic processing method (whole-mount) with standard processing.
Role: PI
Amount: \$2000

K12 ES015855 Brown (PI) July 2008-June 2011
NIH/NIEHS
The Relationship Between Oxidative Stress, Nutritional Exposures/Obesity, and Prostate Cancer
The goal of this study was to establish the association between systemic oxidative stress, obesity and prostate cancer by studying the level of urinary F2 isoprostanes in men undergoing prostate biopsy.
Role: K12 Scholar, Clinical Scientist
Funding: 75% Salary support, MPH tuition and \$26,000 in direct research costs annually.

Grant ID: VR4961 Barocas (PI) January 2012-December 2012
Vanderbilt Institute for Clinical and Translational Research
Factors Associated with Timely Hematuria Evaluation
Retrospective study utilizing Vanderbilt's Research Derivative to determine the variability and opportunity for improvement in the evaluation of persons with blood in the urine.
Role: PI

ACS IRG-58-009-51 Barocas (PI) July 2011-December 2012
American Cancer Society Internal Review Grant

Association Between Race and Surgical Quality of Care for Bladder Cancer

The primary goal of this study is to determine whether there is racial variation in the quality of care for patients undergoing radical cystectomy for bladder cancer.

Role: PI

Total award: \$30,000; no salary support

1R01HS019356-01 Penson (PI) September 2010-August 2013
AHRQ

Comparative Effectiveness of Treatments for Localized Prostate Cancer (CEASAR)

The primary goal of this study is to assemble a large, population-based cohort of men with localized prostate cancer and compare the effectiveness of surgery vs. radiation in the treatment of this common malignancy.

Role: Co-investigator; 35% effort and salary support

CLINICAL TRIALS:

Protocol: L-PC07-169 Michael Cookson (PI) 4-23-08 – 8-29-08

Sponsor: Abbott Endocrine, Inc. (Formerly TAP Pharmaceuticals, Inc.)

Title: A Phase 3, Multi-Center, Open-Label, Trial to Evaluate the Efficacy, Safety and Pharmacokinetics of Two 6-Month Leuprolide Formulations in Subjects with Prostatic Adenocarcinoma. Protocol No. L-PC07-169. Abbott Endocrine, Inc.

Role: Sub-investigator

Protocol: 07TASQ08 Sam Chang (PI) 2-26-08 – 5-31-09

Sponsor: Active Biotech

Title: Phase II Randomized Double Blind Placebo-Controlled Study to Determine the Efficacy of ABR-215050 in Asymptomatic Patients with Metastatic Castrate-Resistant Prostate Cancer

Role: Sub-investigator

Protocol: 14CL403 Sam Chang (PI) January 2009 – continuing

Sponsor: Adolor Corporation

Title: A Phase 4, Multicenter, Double-blind, Placebo-controlled, Parallel Study of Alvimopan for the Management of Postoperative Ileus in Subjects Undergoing Radical Cystectomy

Role: Sub-investigator

Protocol: EN3348-303 Dan Barocas (PI) March 2012 – continuing

Sponsor: ENDO Corporation

Title: A Phase 3, Multicenter, Randomized Controlled Trial of Mycobacterial Cell Wall vs. Mitomycin C for BCG refractory/recurrent non-muscle-invasive bladder cancer.

Role: Site PI

Peer Reviewed Journal Articles:

1. **Barocas D**, Difede J, Viederman M, Madden M, Yurt R. A case of chronic factitious disorder presenting as repeated, self-inflicted burns. *Psychosomatics*, 1998; 39(1):79-80. PMID: 9538680.
2. Difede J, **Barocas D**: Acute intrusive and avoidant PTSD symptoms as predictors of chronic PTSD following burn injury. *J Trauma Stress*, 1999; 12(2): 363-369. PMID: 10378173.
3. **Barocas DA**, Han M, Epstein JI, Chan DY, Trock BJ, Walsh PC, Partin AW. Does capsular incision at radical retropubic prostatectomy affect disease-free survival in otherwise organ-confined prostate cancer? *Urology*, 2001; 58(5):746-51. PMID: 11711353.
4. Difede J, Ptacek JT, Roberts J, **Barocas D**, Rives W, Apfeldorf W, Yurt R: Acute stress disorder after burn injury: a predictor of posttraumatic stress disorder? *Psychosom Med*, 2002; 64(5): 826-34. PMID: 12271114.
5. **Barocas DA**, Steckel J: Commentary on Hospital and surgeon volume: impact on outcomes after radical prostatectomy. *Am J of Urol Rev* 2004; 2(5): 252-4.
6. Shelton JB, **Barocas DA**, Conway F, Hart K, Nelson K, Richstone L, Gonzalez RR, Raman JD, Scherr DS. Prostate-specific antigen screening in a high-risk population: lessons from the community and how they relate to large-scale population-based studies. *Urology*, 2005; 65(5): 931-6. PMID: 15882726.
7. **Barocas DA**, Kawamoto H, Dreizin DF, Howard ME, Choi J, Pitts WR, You X, Tickoo SK, Boorjian SA, Scherr DS. Five-alpha-reductase expression in benign and malignant urothelium; correlation with disease characteristics and outcome. *Urology*, 2005; 66(5): 1134-9. PMID: 16286153.
8. **Barocas DA**, Rabbani F, Scherr DS, Vaughan ED Jr. Population-based study of renal cell carcinoma and prostate cancer in the same patient. *BJU Int*, 2006, 97(1): 33-6. PMID: 16336324.
9. **Barocas DA**, Rohan S, Kao J, Gurevich RD, DelPizzo JJ, Vaughan ED Jr., Akhtar M, Chen YT, Scherr DS. Diagnosis of renal tumors on needle biopsy specimens by histological and molecular diagnosis. *J Urol*, 2006; 176(5): 1957-62. PMID: 17070218.
10. **Barocas DA**, Mathew S, DelPizzo JJ, Vaughan ED Jr., Sosa RE, Fine RG, Akhtar M, Scherr DS. Renal cell carcinoma sub-typing by histopathology and fluorescence in situ hybridization on a needle biopsy specimen. *BJU Int*, 2007; 99(2): 290-5. PMID: 17092279.
11. Pettus JA, al-Ahmadie H, **Barocas DA**, Koppie TM, Herr H, Donat SM, Dalbagni G, Reuter VE, Olgac S, Bochner BH. Risk assessment of prostatic pathology in patients undergoing radical cystoprostatectomy. *Eur Urol*, 2008; 53(2): 370-5. PMID: 17689003.

12. **Barocas DA**, Cowan J, Smith Jr, JA, Carroll PR. What percentage of patients with newly-diagnosed carcinoma of the prostate are candidates for surveillance? An analysis of the CaPSURE Database. *J Urol*, 2008; 180(4): 1330-4. PMID: 18707731.
13. Wang GJ, **Barocas DA**, Raman JD, Scherr DS. Robotic versus open radical cystectomy: prospective comparison of perioperative outcomes and pathologic measures of early oncologic efficacy. *BJU Int*, 2008; 101(1): 89-93. PMID: 17888044.
14. Chan R, **Barocas DA**, Chang SS, Herrell SD, Clark PE, Baumgartner R, Smith Jr JA, Cookson MS. Impact of large prostate gland size on open and robotic assisted laparoscopic radical prostatectomy. *BJU Int*, 2008; 101(9): 1140-4. PMID: 18399829.
15. **Barocas DA**, Clark PE: Bladder Cancer. *Curr Opin Oncol*, 2008; 20(3): 307-14. PMID: 8391631.
16. Kauffman EC, **Barocas DA**, Chen YT, Yang XJ, Scherr DS, Tu JJ. Differential expression of the KAI1 metastasis suppressor protein in renal cell tumor histologic subtypes. *J Urol*, 2009; 181(5):2305-11. PMID: 19303095.
17. Boudreax, Jr., KJ, Clark PE, Lowrance WT, Rumohr JA, **Barocas DA**, Cookson MS, Smith JA Jr, Chang SS. Comparison of American Joint Committee on Cancer pathologic stage T2a versus T2b urothelial carcinoma: Analysis of patient outcomes in organ-confined bladder cancer. *J Urol*, 2009; 181(2):540-5. PMID: 19084855.
18. Boudreax, Jr., KJ, Chang SS, Lowrance WT, Rumohr JA, **Barocas DA**, Cookson MS, Smith JA Jr, Clark PE. Comparison of American Joint Committee on Cancer pathologic stage T3a versus T3b urothelial carcinoma of the bladder: Analysis of patient outcomes. *Cancer* 2009, 115(4):770-5. PMID: 19152431.
19. Mitchell, RE, Lee BT, Cookson MS, **Barocas DA**, Herrell SD, Clark PE, Smith JA Jr, Chang SS. Radical nephrectomy surgical outcomes in the University HealthSystem Consortium Database: impact of hospital case volume, hospital size and geographic location on 40,000 patients. *Cancer*, 2009; 115(11): 2447-52. PMID: 19309750.
20. Mitchell, RE, Lee BT, Cookson MS, **Barocas DA**, Herrell SD, Clark PE, Smith JA Jr, Chang SS. Immediate surgical outcomes for radical prostatectomy in the University HealthSystem Consortium Database: impact of hospital case volume, hospital size and geographic location on 48,000 patients. *BJU Int*, 2009; 104(10): 1442-5. PMID: 19681895.
21. Patel SG, Cookson MS, **Barocas DA**, Clark PE, Smith JA Jr, Chang SS. Risk factors for urothelial carcinoma of the prostate in patients undergoing radical cystoprostatectomy for bladder cancer. *BJU Int*, 2009; 104(7): 934-7. PMID: 19338554.
22. **Barocas DA**, Patel SG, Chang SS, Clark PE, Smith JA Jr, Cookson MS. Outcomes of patients undergoing radical cystoprostatectomy for bladder cancer with prostatic involvement on final pathology. *BJU Int*, 2009; 104(8): 1091-7. PMID: 19389006.

23. **Barocas DA**, Mitchell RE, Chang SS, Cookson MS. Impact of surgeon and hospital volume on outcomes of prostatectomy. *Urol Oncol*, 2010; 28(3): 243-50. PMID: 19395287.
24. Kordan Y, Chang SS, Salem S, Cookson MS, Clark PE, Davis R, Herrell SD, Baumgartner R, Phillips S, Smith JA Jr, **Barocas DA**. Pathologic stage T2 subgroups to predict biochemical recurrence after prostatectomy. *J Urol*, 2009; 182(5): 2291-5. PMID: 19758638.
25. Kordan Y, Salem S, Chang SS, Clark PE, Cookson MS, Davis R, Herrell SD, Baumgartner R, Phillips S, Smith JA Jr, **Barocas DA**. Impact of positive apical surgical margins on the likelihood of biochemical recurrence after radical prostatectomy. *J Urol*, 2009; 182(6): 2695-701. PMID: 19836759.
26. **Barocas DA**, Salem S, Kordan Y, Herrell SD, Chang SS, Clark PE, Davis R, Baumgartner R, Phillips S, Cookson MS, Smith JA Jr. Robotic-assisted laparoscopic prostatectomy versus radical retropubic prostatectomy for clinically localized prostate cancer: comparison of short-term biochemical recurrence-free survival. *J Urol*, 2010; 183(3): 990-6. PMID: 20083261.
27. Salem S, Chang SS, Clark PE, Davis R, Herrell SD, Kordan Y, Shappell S, Wills M, Baumgartner R, Phillips S, Smith JA Jr, Cookson MS, **Barocas DA**. Comparative analysis between whole mount processing and systematic sampling of radical prostatectomy specimens: pathological outcomes and risk of biochemical recurrence. *J Urol*, 2010; 184(4) : 1334-40. PMID: 20723932.
28. Kordan Y, **Barocas DA**, Altamar HO, Clark PE, Chang SS, Davis R, Herrell SD, Salem S, Baumgartner R, Mishra V, Chan R, Smith JA Jr, Cookson MS. Comparison of transfusion requirements between open and robotic assisted laparoscopic radical prostatectomy. *BJU Int*, 2010; 106(7): 1036-40. PMID: 20151960.
29. Stimson CJ, Cookson MS, **Barocas DA**, Clark PE, Humphrey JE, Patel SG, Smith JA Jr, Chang SS. Preoperative hydronephrosis predicts extravesical and node positive disease in patients undergoing cystectomy for bladder cancer. *J Urol*, 2010; 183(5): 1732-7. PMID: 20299043.
30. Newton MR, Phillips S, Chang SS, Clark PE, Cookson MS, Davis R, Fowke JH, Herrell SD, Chan R, Blume JD, Smith JA Jr, **Barocas DA**. Small Prostate Size Predicts High-Grade Prostate Cancer At Final Pathology. *J Urol*, 2010; 184(3), 930-7. PMID: 20643423.
31. **Barocas DA**, Chang SS. Penile cancer presentation, diagnosis and staging. *Urol Clin North Am*, 2010; 37(3): 343-52. PMID: 20674691.
32. **Barocas DA**, Penson DF. Racial variation in the pattern and quality of care for prostate cancer in the US: mind the gap. *BJU Int*, 2010; 106(3): 322-8. PMID: 20553251.
33. Stimson CJ, Chang SS, **Barocas DA**, Humphrey JE, Patel SG, Clark PE, Smith JA Jr, Cookson, MS. Early and late perioperative outcomes following radical cystectomy: 90-day

- readmissions, morbidity and mortality in a contemporary series. *J Urol*, 2010; 184(4): 1296-300. PMID: 20723939.
34. Thompson, III IM, Salem S, Chang SS, Clark PE, Davis R, Herrell SD, Kordan Y, Baumgartner R, Phillips S, Smith JA Jr, Cookson MS, **Barocas DA**. Tumor volume as a predictor of adverse pathologic features and biochemical recurrence in radical prostatectomy specimens: a tale of two methods. *World J Urol*, 2010; 29(1): 15-20. PMID 21079968.
 35. Aghazadeh MA, **Barocas DA**, Salem S, Clark PE, Cookson MS, Davis R, Gregg J, Stimson CJ, Smith JA Jr, Chang SS. Determining factors for hospital discharge status after radical cystectomy in a large contemporary cohort. *J Urol*, 2011; 185(1): 85-9. PMID: 21074199.
 36. Gregg JR, Cookson MS, Phillips S, Salem S, Chang SS, Clark PE, Davis R, Stimson CJ, Smith JA Jr, **Barocas DA**. Effect of pre-operative nutritional status on mortality after radical cystectomy for bladder cancer. *J Urol*, 2011; 185(1): 90-6. PMID: 21074802.
 37. Salem S, Mitchell, III RE, El-doraey AE-A, Smith JA Jr, **Barocas DA**. Successful control of schistosomiasis and the changing epidemiology of bladder cancer in Egypt. *BJU Int*, 2011; 107(2): 206-11. PMID: 21208365.
 38. Fowke JH, Motley SS, **Barocas DA**, Cookson MS, Concepcion R, Byerly S, Smith JA Jr. The associations between statin use and prostate cancer screening, prostate size, high-grade prostatic intraepithelial neoplasia (PIN), and prostate cancer. *Cancer Causes Control*, 2011; 22(3): 417-26. PMID: 21170754.
 39. Morgan TM, Tang D, Stratton KL, **Barocas DA**, Anderson CB, Gregg JR, Chang SS, Cookson MS, Herrell SD, Smith JA Jr, Clark PE. Preoperative nutritional status is an important predictor of survival in patients undergoing surgery for renal cell carcinoma. *Eur Urol*, 2011; 59(6): 923-8. PMID: 21295907.
 40. **Barocas DA**, Motley S, Cookson MS, Chang SS, Penson DF, Dai Q, Milne G, Roberts, II, LJ, Morrow J, Concepcion R, Smith JA Jr, Fowke JH. Oxidative stress measured by urine F2-isoprostane level is associated with prostate cancer. *J Urol*, 2011; 185(6): 2102-7. PMID: 21496850.
 41. Dai Q, Motley SS, Smith JA Jr, Concepcion R, **Barocas D**, Byerly S, Fowke JH. Blood magnesium, and the interaction with calcium, on the risk of high-grade prostate cancer. *PLoS One*, 2011; 6(4): e18237. PMID: 21541018.
 42. Davies JD, Aghazadeh MA, Phillips S, Salem S, Chang SS, Clark PE, Cookson MS, Davis R, Herrell SD, Penson DF, Smith JA Jr, **Barocas DA**. Prostate size as a predictor of Gleason score upgrading in low-risk prostate cancer patients. *J Urol*, 2011; 186(6):2221-7. PMID:22014803.
 43. Morgan TM, Keegan KA, **Barocas DA**, Ruhotina N, Phillips, S, Chang SS, Penson DF, Clark PE, Smith JA Jr., Cookson MS. Predicting the probability of 90-day survival in elderly bladder

- cancer patients treated with radical cystectomy. *J Urol*, 2011; 186(3): 829-34. PMID: 21788035.
44. Patel SG, Penson DF, Pabla B, Clark PE, Cookson MS, Chang SS, Herrell SD, Smith JA Jr, **Barocas DA**. National trends on the utilization of partial nephrectomy: a rising tide that has not lifted all boats. *J Urol*, 2012; 187(3): 816-21. PMID: 22248514.
 45. Fowke JH, Motley SS, Concepcion RS, Penson DF, **Barocas DA**. Obesity, body composition, and prostate cancer. *BMC Cancer*, 2012; 12(1): 23. PMID: 22257467.
 46. Morgan TM, **Barocas DA**, Chang SS, Phillips S, Salem S, Clark PE, Penson DF, Smith JA Jr, Cookson MS. The relationship between perioperative blood transfusion and overall mortality in patients undergoing radical cystectomy for bladder cancer. *Urol Oncol*, Epub ahead of print September 7, 2011. PMID: 21906965.
 47. Broughton GJ, Clark PE, **Barocas DA**, Cookson MS, Smith JA Jr, Herrell SD, Chang SS. Tumor size, R.E.N.A.L. nephrometry score, and surgical approach are the determinants of nephrectomy type for small renal cortical tumors treated electively. *BJU Int*, 2012; 109(11): 1607-13. PMID: 21939493.
 48. Anderson CB, Feurer ID, Large MC, Steinberg GD, **Barocas DA**, Cookson MS, Penson DF. Psychometric characteristics of a condition-specific, health-related quality-of-life survey: the FACT-Vanderbilt Cystectomy Index. *Urology*, 2012; 80(1): 77-83. PMID: 22608798.
 49. **Barocas DA**, Globe DR, Colayco DC, Onyenwenvi A, Bruno AS, Bramley TJ, Spear RJ. Surveillance and treatment of non-muscle invasive bladder cancer in the US. *Advances in Urology*, 2012; 2012:421709. PMID: 22645607.
 50. **Barocas DA**, Gray DT, Fowke JH, Mercaldo ND, Blume JD, Chang SS, Cookson MS, Smith JA Jr, Penson DF. Racial variation in the quality of surgical care for prostate cancer. *J Urol*, 2012; 188(4): 1279-85. PMID: 22902011.
 51. Anderson CB, Kaufman MR, Dietrich MS, **Barocas DA**, Chang SS, Cookson MS, Smith JA Jr, Clark PE, Herrell SD. Recovery of urinary function after radical prostatectomy: identification of trajectory cluster groups. *J Urol*, 2012; 187(4): 1346-51. PMID: 22341278.
 52. Anderson CB, Pyle AL, Woodworth A, Cookson MS, Smith JA Jr, **Barocas DA**. Spurious elevation of serum prostate-specific antigen after curative treatment for prostate cancer: clinical consequences and the role of heterophilic antibodies. *Prostate Cancer Prostatic Dis*, 2012; 15(2): 182-8. PMID: 22105412.
 53. Morgan TM, **Barocas DA**, Keegan KA, Cookson MS, Chang SS, Clark PE, Ni S, Smith JA Jr, Penson DF. Volume-outcomes in cystectomy: is it the surgeon or the setting? *J Urol*, 2012; 188(6): 2139-44. PMID: 23083864.

54. Lee CT, **Barocas DA**, Globe DR, Oefelein MG, Colayco DC, Gilmore, A, O'Day K, Bramley T. Economic and humanistic consequences of preventable bladder tumor recurrences in non-muscle invasive bladder cancer. *J Urol*, 2012; 188(6): 2114-0. PMID: 23083857.
55. Kaffenberger SD, Keegan KA, Bansal NK, Morgan TM, Tang DH, **Barocas DA**, Penson DF, Davis R, Clark PE, Chang SS, Cookson MS, Herrell SD, Smith JA Jr. Salvage Robotic-Assisted Laparoscopic Radical Prostatectomy: A Single Institution, Five-Year Experience. *J Urol*, 2013; 189(2): 507-13. PMID: 23000849.
56. Kaffenberger SD, Morgan TM, Stratton K, Boachie A, **Barocas DA**, Chang SS, Cookson MS, Herrell SD, Smith JA Jr, Clark PE. ABO blood group is a predictor of survival in patients undergoing surgery for renal cell carcinoma. *BJUI*, Epub ahead of print, September 7, 2012. PMID: 22958439.
57. Morgan TM, **Barocas DA**, Penson DF, Chang SS, Ni S, Clark PE, Smith JA Jr, Cookson MS. Lymph Node Yield at Radical Cystectomy Predicts Mortality in Node-negative and not Node-positive Patients. *Urology*, 2012; 80(3): 632-40. PMID: 22795379.
58. Anderson CB, Morgan TM, Kappa S, Moore D, Clarke PE, Davis R, Penson DF, **Barocas DA**, Smith JA Jr, Cookson MS, Chang SS. Ureteroenteric Anastomotic Strictures after Radical Cystectomy: Does Operative Approach Matter? *J Urol*, 2013; 189(2): 541-7. PMID: 23260561.
59. Ramsay C, Pickard R, Robertson C, Close A, Vale L, Armstrong N, **Barocas DA**, Eden C, Fraser C, Gurung T, Jenkinson D, Jia X, Lam T, Mowatt G, Neal D, Robinson M, Royle J, Rushton S, Sharma P, Shirley M, Soomro N. Systematic review and economic modeling of the relative clinical benefit and cost-effectiveness of laparoscopic surgery and robotic surgery for removal of the prostate in men with localised prostate cancer. *Health Technol Assess*, 2012; 16(41):1-313. PMID: 23127367.
60. Davis R, Jones JS, **Barocas DA**, Castle EP, Lang EK, Leveille RJ, Messing EM, Miller SD, Peterson AC, Turk TMT, Weitzel W. Diagnosis, evaluation and follow-up of asymptomatic microhematuria in adults: AUA Guideline. *J Urol*, 2012; 188(6 Suppl): 2473-81. PMID: 23098784.
61. Penson DF, **Barocas DA**, Fleshner N, Sanda MG, Greenfield S. Randomized trials and observational studies for comparative effectiveness research: Outcomes Session of the Winter 2011 SUO Meeting. *Urologic Oncology*, 2012; 30(6): 952-5.
62. Anderson CB, Penson DF, Ni S, Makarov DV, **Barocas DA**. Centralization of radical prostatectomy in the United States. *J Urol*, 2013; 189(2): 500-6. PMID: 23069384.
63. **Barocas DA**, Grubb III R, Black A, Penson DF, Fowke JH, Andriole G, Crawford ED. Association between race and follow-up diagnostic care after a positive prostate cancer screening test in the PLCO trial. *Cancer*, 2013; 119(12): 2223-9. PMID: 23559420.

64. Gallagher SA, Smith A, Matthews JE, Potter CW, Woods ME, Raynor M, Wallen EM, Tathmell K, Whang YE, Kim WY, Godley PA, Chen RC, Wang A, You C, **Barocas DA**, Pruthi RS, Nielsen ME, Milowsky MI. Roadmap for the Development of the University of North Carolina at Chapel Hill Genitourinary OncoLogy Database - UNC GOLD Urologic Oncology. *Urol Oncol*, 2013. Epub ahead of print. PMID: 23434424.
65. Davies JD, Simons CM, Ruhotina N, **Barocas DA**, Clark PE, Morgan TM. Anatomical basis for pelvic lymph node dissection for bladder cancer: an autopsy study. *Urology*, 2013; 81(2): 358-63. PMID: 23374802.
66. Fowke JH, Motley DD, Dai Q, Concepcion R, **Barocas DA**. Association between Markers of Obesity and Risk of High-Grade Prostatic Intraepithelial Neoplasia and Prostate Cancer - Evidence of Effect Modification by Prostate Size. *Cancer Letters*, 2013; 328(2): 345-52. PMID: 23079532.
67. **Barocas DA**, Burks FN, Suh RS, Schuster TG, Bradford T, Moylan DA, Knapp PM, Murtagh DS, Morris D, Dunn RL, Montie JE, Miller DC, Liu A. Practice-based collaboration to improve the use of immediate intravesical therapy after resection for non-muscle-invasive bladder cancer: Urologic Surgery Quality Collaborative (USQC). *Journal of Urology* 2013; 190(6): 2011-6. PMID: 23792129.
68. **Barocas DA**, Chen V, Cooperberg M, Goodman M, Graff JJ, Greenfield S, Hamilton A, Hoffman K, Kaplan S, Koyama T, Morgans A, Paddock LE, Phillips S, Resnick MJ, Stroup A, Wu XC, Penson DF. Using a population-based observational cohort study to address difficult comparative effectiveness research questions: The CEASAR study. *J Comp Eff Res*, 2013; 2(4), 445-60. PMID:24236685.
69. Thompson IM 3rd, Kappa SF, Morgan TM, **Barocas DA**, Bischoff CJ, Keegan KA, Stratton KL, Clark PE, Resnick MJ, Smith JA Jr, Cookson MS, Chang SS. Blood loss associated with radical cystectomy: A prospective, randomized study comparing Impact LigaSure vs. stapling device. *Urol Oncol*, 2014 ;32(1): 45.e11-5. PMID: 24054870.
70. Ark JT, Keegan KA, **Barocas DA**, Morgan TM, Resnick MJ, You C, Cookson MS, Penson DF, Davis R, Clark PE, Smith JA Jr, Chang SS. Incidence and Predictors of Understaging in Patients with Clinical T1 Urothelial Carcinoma Undergoing Radical Cystectomy. *BJU Int*, 2013. 113(6):894-9. PMID: 24053444.
71. Patel SG, Stimson CJ, Zaid HB, Resnick MJ, Cookson MS, **Barocas DA**, Chang SS. Locoregional Small Cell Carcinoma of the Bladder: Clinical Characteristics and Treatment Patterns in Over 600 Patients from the National Cancer Database. *J Urol*, 2013. 191(2):329-34 PMID: 24036236.
72. **Barocas DA**, Kulahalli CS, Ehrenfeld JM, Kapu AN, Penson DF, You C, Weavind L, Dmochowski R. Bench-marking the use of a rapid response team by surgical services at a tertiary care hospital. *J Am Coll Surg* 2014; 218(1): 66-72. PMID: 24275072.

73. Reardon ZD, Patel SG, Stimson CJ, Zaid HB, **Barocas DA**, Resnick MJ, Chang SS, Cookson MS. Trends in the use of Perioperative Chemotherapy for Localized and Locally Advanced Muscle-Invasive Bladder Cancer: A Sign of Changing Tides. *Euro Urol*. 2015 Jan;67(1):165-70.doi:10.1016/j.eururo.2014.01.009.Epub 2014 Jan 23. PMID: 24472710.
74. Shore ND, Concepcion R, **Barocas DA**. A urologic oncology roundtable discussion: the role of disease monitoring in treatment decision-making for patients with metastatic castration-resistant prostate cancer. *Hospital Practice*, 2013; 41(4): 78-80. PMID: 24145592.
75. Zaid HB, Patel SG, Stimson CJ, Resnick MJ, Cookson MS, **Barocas DA**, Chang SS. Trends in the Utilization of Neoadjuvant Chemotherapy in Muscle-Invasive Bladder Cancer: Results from the National Cancer Database. *Urology*, 2013. 83(1):75-80. PMID: 24231210.
76. Friedlander DF, Resnick MJ, You C, Bassett J, Yargaladda V, Penson DF, **Barocas DA**. Variation in use of diagnostic testing for hematuria evaluation: a quality of care concern in primary care clinics. *Am J Med*, 2014. 127(7):633-640. PMID: 24486290.
77. **Barocas DA**, Bensink ME, Berry K, Musa Z, Bodnar C, Dann R, Ramsey SD. Potential cost-effectiveness of a diagnostic that identifies localized versus metastatic prostate cancer in men with biochemical recurrence after radical prostatectomy. *International Journal of Technology Assessment in Health Care*, 2014 Oct;30(4):345-53.doi:10.1017/S0266462314000476.Epub 2014 Nov 17. PMID: 25399914.
78. Resnick MJ, **Barocas DA**, Morgans AK, Phillips SE, Chen VW, Cooperberg MR, Goodman M, Greenfield S, Hamilton AS, Hoffman KE, Kaplan SH, Paddock LE, Stroup AM, Wu XC, Koyama T, Penson DF. Contemporary prevalence of pretreatment urinary, sexual, hormonal, and bowel dysfunction: Defining the population at risk for harms of prostate cancer treatment. *Cancer* 2014. 15;120(8):1263-71. PMID: 24510400.
79. **Barocas DA**, Alvarez J, Koyama T, Anderson CB, Gray DT, Fowke JH, You C, Chang SS, Cookson MS, Smith Jr. JA, Penson D. Racial Variation in the Quality of Surgical Care for Bladder Cancer. *Cancer* 2013. 120(7):1018-25. PMID: 24339051.
80. Ritch CR, You C, May AT, Herrell SD, Clark PE, Penson DF, Chang SS, Cookson MS, Smith Jr. JA, **Barocas DA**. Biochemical recurrence-free survival after robotic-assisted laparoscopic vs. open radical prostatectomy for intermediate and high-risk prostate cancer. *Urology*, 2014. 83(6):1309-15. PMID: 24746665.
81. Eifler JB, **Barocas DA**, Resnick MJ. Predictors of Outcome in Bladder Cancer. *JNCCN*, 2014. 12(11): 1549-54. PMID: 25361801.
82. Stimson CW Jr., Resnick MJ, Patel SG, Zaid HB, Cookson MS, Penson DF, Smith JA Jr., Chang SS, **Barocas DA**. The Influence of Access-Related Factors on Adherence to Clinical Practice Guidelines for Muscle-Invasive Bladder Cancer. *Urology Practice*, 2014; 1(3): 127-33.

83. Ritch CR, Cookson MS, Chang SS, Clark PE, Resnick MJ, Penson DF, Smith JA Jr., May AT, Anderson CB, You C, Lee H, **Barocas DA**. Impact of Complications and Hospital-Free Days following Radical Cystectomy on Health-Related Quality of Life at One Year. *J Urol*, 2014. 83(6):1360-4.398:10.1016/j.juro.2014.06.004. PMID: 24928268.
84. Anderson CB, Alvarez J, Koyama T, Penson DF, **Barocas DA**. The impact of gender on utilization of pelvic lymphadenectomy at the time of radical cystectomy. *Urology Practice*, 2014; 1(3): 146-50.
85. Ritch C, Graves AJ, Keegan KA, Ni S, Bassett JC, Chang SS, Resnick MJ, Penson DF, **Barocas DA**. Increasing use of observation among men at low risk for prostate cancer mortality. *J Urol*, 2015. Mar;193(3):801-6.doi:10.1016/j.juro.2014.08.102 . PMID: 25196658.
86. Zargar H, Espiritu PN, Fairey AS, Mertens L, Dinney CP, Mir MC, Ercole CE, Krabbe L-M, Cookson MS, Jacobsen N-E, Gandhi N, Griffin J, Montgomery JS, Vasdev N, Yu EY, Youssef D, Xylinas E, Campain NJ, Kassouf W, Dall'Era MA, Seah J-A, Sridhar SS, Aning J, Shariat SF, Wright JL, Thorpe AC, Holzbeierlein JM, Bivalacqua TJ, North S, **Barocas DA**, Lotan Y, Garcia JA, Stephenson AJ, Shah JB, van Rhijn BW, Daneshmand S, Spiess PE, Black P. Multicenter assessment of neoadjuvant chemotherapy for muscle-invasive bladder cancer. *Euro Urol*, Epub ahead of print, Sept 23, 2014. PMID: 25257030.
87. Resnick MJ, **Barocas DA**, Morgans AK, Phillips SE, Koyama T, Albertsen PC, Cooperberg MR, Goodman M, Greenfield S, Hamilton AS, Hoffman KE, Hoffman RM, Kaplan SH, McCollum D, Paddock LE, Stanford JL, Stroup AM, Wu XC, Penson DF. The Evolution of Self-Reported Urinary and Sexual Dysfunction over the Last Two Decades: Implications for Comparative Effectiveness Research. *Euro Urol*, Epub ahead of print Aug 28, 2014. Pii:S0302-2838(14)00788-X.doi:10.1016/j.eururo.2014.08.035. PMID: 25174325.
88. Lipworth L, Morgans AK, Edwards TL, **Barocas DA**, Chang SS, Herrell SD, Penson DF, Resnick MR, Smith JA Jr, Clark PE. Renal cell cancer histologic subtype distribution differs by race and sex. *BJUI*, Epub ahead of print Oct 13, 2014.doi: 10.1111/bju.12950. PMID: 25307281.
89. Carroll PR, Parsons JK, Andriole G, Bahnson RR, **Barocas DA**, Catalona WJ, Dahl DM, Davis JW, Epstein JI, Etzioni RB, Giri VN, Hemstreet GP 3rd, Kawachi MH, Lange PH, Loughlin KR, Lowrance W, Maroni P, Mohler J, Morgan TM, Nadler RB, Poch M, Scales C, Shanefelt TM, Vickers AJ, Wake R, Shead DA, Ho M. Prostate cancer early detection, version 1.2014. Featured updates to the NCCN Guidelines. *JNCCN*, 2014. 12(9):1211-9. PMID: 25190691.
90. **Barocas DA**, Davis R. AUA Update. Evaluation and Management of Asymptomatic Microhematuria. 2014.
91. Bassett JC, Gore JL, Kwan L, Ritch CR, **Barocas DA**, Penson DF, McCarthy WJ, Saigal CS. Knowledge of the harms of tobacco use among patients with bladder cancer. *Cancer*. 2014 Dec 15;120(24):3914-22.doi:10.1002/cncr.28915.Epub 2014 Nov 10. PMID: 25385059.
92. Morgans AK, Fan K-H, Koyama T, Albertsen PC, Goodman M, Hamilton AS, Hoffman R, Stanford J, Stroup AM, Resnick MJ, **Barocas DA**, Penson DF. Influence of Age on Incident

- Diabetes and Cardiovascular Disease Among Prostate Cancer Survivors Receiving Androgen Deprivation Therapy. *J Urol*. 2014 Nov 11. Pii: S0022-5347(14)04835-6. Doi:10.1016/j.juro.2014.11.006. PMID:25451829.
93. Kaffenberger S, Lin-Tsai O, Stratton KL, Morgan TM, **Barocas DA**, Chang SS, Cookson MS, Herrell SD, Smith Jr, JA, Clark PE. Statin Use is Associated with Improved Survival in Patients Undergoing Surgery for Renal Cell Carcinoma. *Urol Oncol*. 2015 Jan;33(1):21.e11-7. PMID: 25456998.
94. Bassett JC, Alvarez JM, Koyama T, Resnick MJ, You C, Ni S, Penson DF, **Barocas DA**. Gender, race, and variation in the workup of hematuria. *JGIM*, In press. 2014 Dec 2. PMID: 25451992.
95. Smith ND, Castle EP, Gonzalgo ML, Svatek RS, Weizer AK, Montgomery JS, Pruthi RS, Woods ME, Tollefson MK, Konety BR, Shabsigh A, Krupski T, **Barocas DA**, Dash A, Quek ML, Kibel AS, Parekh DJ. The RAZOR (randomized open vs robotic cystectomy) trial: study design and trial update. *BJU Int*. 2015 Feb;115(2):198-205.doi:10.1111/bju.12699. PMID: 25626182.
96. Eggener SE, Badani K, **Barocas DA**, Barrisford GW, Cheng JS, Chin AI, Corcoran A, Epstein JI, George AK, Gupta GN, Hayn MH, Kauffman EC, Lane B, Liss MA, Mirza M, Morgan TM, Moses K, Nepple KG, Preston M, Rais-Bahrami S, Resnick MJ, Siddiqui MM, Silberstein J, Singer EA, Sonn GA, Sprenkle P, Stratton KL, Taylor J, Tomaszewski J, Tollefson M, Vickers A, White WM, Lowrance WT. Gleason 6 Prostate Cancer: Translating Biology Into Population Health. *J Urol*. 2015 Apr 4. pii: S0022-5347(15)03689-7. doi: 10.1016/j.juro.2015.01.126. [Epub ahead of print]. PMID: 25849602.
97. Reddy OL, Cates JM, Gellert LL, Crist HS, Yang Z, Yamashita H, Taylor JA 3rd, Smith JA Jr, Chang SS, Cookson MS, You C, **Barocas DA**, Grabowska MM, Ye F, Wu XR, Yi Y, Matusik RJ, Kaestner KH, Clark PE, DeGraff DJ. Loss of FOXA1 Drives Sexually Dimorphic Changes in Urothelial Differentiation and Is an Independent Predictor of Poor Prognosis in Bladder Cancer. *Am J Pathol*. 2015 May;185(5):1385-95. doi: 10.1016/j.ajpath.2015.01.014. PMID: 25907831
98. Moore DC, Resnick MJ, **Barocas DA**, Davis R, Cookson MS, Clark PE, Herrell SD, Kulahalli CS, Giannico G, Smith Jr. JA, You C, Chang SS. Predictors of Recurrence in Patients with High-Risk Pathology after Prostatectomy. *Int J Research in Urology*. Vol. 2015 (2015), Article ID 356402, DOI: 10.5171/2015.356402
99. Joshi SS, Sohn W, Sun D, Clark PE, Barocas DA, Resnick MJ, Cookson MS, Smith JA, Chang SS. Follow-up imaging in the first two years after nephrectomy for T1 RCC: Over-use or necessary care? *Journal of Clinical Urology* 2051415815581096, first published on April 9, 2015 doi:10.1177/2051415815581096
- 100.
101. Barocas DA, Mallin K, Graves AJ, Penson DF, Palis B, Winchester DP, Chang SS. The effect of the United States Preventive Services Task Force grade D recommendation against screening

for prostate cancer on incident prostate cancer diagnoses in the US. J Urol. 2015 Jun 15. pii: S0022-5347(15)04209-3. doi: 10.1016/j.juro.2015.06.075. [Epub ahead of print]. PMID: 26087383

102. Eifler JB, Sohn W, **Barocas DA**. Best Evidence Regarding Contemporary Use of Prostate Cancer Biomarkers. J Urol Practice, in press.

Book Chapters:

Barocas DA: Adrenal Physiology. In Leslie, S (ed.). Urology Board Review: Pearls of Wisdom. Third Edition. New York, McGraw Hill, 2009.

Barocas DA, Cookson MS: Surgical management of clinically localized prostate cancer. In Dmochowski RR, Dahm P (eds). Evidence-Based Urology. British Medical Journal Publishing Group, 2010.

Barocas DA, Scherr DS: Ileal Conduit. In Smith Jr. JA, Howards S, McGuire E, Preminger GM. (eds). Hinman's Atlas of Urology, 3rd Edition. Philadelphia, Elsevier, 2012.

Resnick, MJ, **Barocas DA**: Adrenal Physiology. In Leslie, S (ed.). Urology Board Review: Pearls of Wisdom. Fourth Edition. New York, McGraw Hill, 2013.

Boorjian SA, Raman JD, **Barocas DA**: Evaluation and Management of Hematuria. In Wein, Kavoussi, Partin & Peters (Eds), Campell-Walsh Urology, 9th Edition, In press.

Published letters and editorials:

Barocas DA, Richstone L, Kavoussi LR. Letter to the editor, re: A multi-institution, minimally invasive urological oncology fellowship: a critical assessment of clinical training and academic benefits. J Urol 2007, 177: 2400. PMID: 17509376

Barocas DA. Decreasing overtreatment by promoting active surveillance will depend upon identifying superior markers of aggressive disease. Journal of Urology 2010, 183(1):143-4. PMID:19913807

Barocas DA. Beware the small prostate. Journal of Urology 2012, 187(2):481. PMID:22177148.

Anderson CB, **Barocas DA**. Delivering high-quality care to prostate cancer survivors. Cancer. 2013. Epub ahead of print. PMID: 23893779.

CONFERENCE PRESENTATIONS AND PUBLISHED ABSTRACTS:

1. Difede J, **Barocas DA**, Martone M, Roberts J, Yurt R. Acute stress disorder following burn injury as a predictor of chronic PTSD. Poster presented at the Association for the Advancement of Behavior Therapy annual meeting, November 1996, New York, NY.
2. Difede J, **Barocas DA**, Eskra D, Jaffe A, Roberts J, Yurt R. Acute stress disorder following burn injury. In symposium, "Acute Stress Reactions to Traumatic Events". American Psychiatric Association annual meeting, May 1997, San Diego, CA.
3. Lambert J, **Barocas DA**, Roberts J, Difede J. Attribution of blame, self-esteem, and acute stress disorder following burn injury. Poster presented at the Society for Behavioral Medicine annual meeting, April 1997, San Francisco, CA.
4. Difede J, **Barocas DA**, Roberts J, Eskra D, Burkhalter J, Fleming M, Yurt R. Predictors of acute stress disorder following burn injury. Paper presented at the American Burn Association annual meeting, March 1997, New York, NY.
5. **Barocas DA**, Han M, Epstein JI, Chan DY, Trock BJ, Walsh PC, Partin AW. Does capsular incision at radical retropubic prostatectomy affect disease-free survival in otherwise organ-confined prostate cancer? Poster at American Urological Association annual meeting, May 2001, Anaheim, CA.
6. **Barocas DA**, Rabbani F, Scherr D, Vaughan ED Jr. Population based study of renal cell carcinoma and prostate cancer in the same patient. Poster at American Urological Association annual meeting, May 2005, San Antonio, TX.
7. **Barocas DA**, Chen YT, Kao J, DelPizzo JJ, Vaughan ED Jr, Akhtar M, Scherr DS. Diagnosis and subtyping of renal cell carcinoma on needle biopsy specimens using histopathology and a molecular diagnostic algorithm. Poster at World Congress of Endourology annual meeting, August 2005, Amsterdam, The Netherlands.
8. **Barocas DA**, Mathew S, DelPizzo JJ, Vaughan ED Jr, Gurevich R, Akhtar M, Scherr DS. Renal cell carcinoma sub-typing by histopathology and fluorescence in-situ hybridization on a needle biopsy specimen. Poster at Society of Urologic Oncology annual meeting, December 2005, Bethesda, MD.
9. **Barocas DA**, Chen YT, Rohan S, Kao J, DelPizzo JJ, Vaughan ED Jr, Gurevich R, Akhtar M, Scherr DS. Renal cell carcinoma sub-typing by real-time PCR on needle biopsy. Podium Presentation at Society Of Urologic Oncology annual meeting, December 2005, Bethesda, MD.
10. Boorjian SA, Kawamoto H, Dong S, **Barocas DA**, Smith E, You X, Pitts WR, Tickoo S, Akhtar M, Scherr DS. Hormone regulation of transitional cell carcinoma of the bladder. Poster at Society Of Urologic Oncology annual meeting, December 2005, Bethesda, MD.
11. Boorjian SA, Kawamoto H, Dong S, **Barocas DA**, You X, Pitts WR, Tickoo SK, Akhtar M, Scherr DS. Molecular evidence for hormonal regulation of bladder cancer. Poster at American Urological Association annual meeting, May 2006, Atlanta, GA.

12. Pettus J, Al-Ahmadie H, **Barocas DA**, Vora K, Dalbagni G, Donat SM, Olgac S, Bochner B. Prostate involvement by urothelial and prostatic carcinomas in radical cystoprostatectomy specimens. Poster at American Urological Association annual meeting, May 2006, Atlanta, GA.
13. **Barocas DA**, Mathew S, DelPizzo JJ, Vaughan ED Jr, Gurevich RD, Akhtar M, Scherr DS. Renal cell carcinoma sub-typing by histopathology and fluorescence in-situ hybridization on a needle biopsy specimen. Poster at American Urological Association annual meeting, May 2006, Atlanta, GA.
14. **Barocas DA**, Rohan S, Kao J, DelPizzo JJ, Vaughan ED Jr, Gurevich RD, Akhtar M, Chen YT, Scherr DS. Renal cell carcinoma sub-typing by real-time PCR on needle biopsy. Poster at American Urological Association annual meeting, May 2006, Atlanta, GA.
15. **Barocas DA**, Gurevich RD, Ng CK, Zhou KX, Mazumdar M, Vaughan ED Jr, DelPizzo JJ, Scherr DS. Is elevated body mass index a risk factor for aggressive pathologic findings at nephrectomy? Poster at American Urological Association annual meeting, May 2006, Atlanta, GA.
16. **Barocas DA**, Gurevich RD, Ng CK, Zhou KX, Mazumdar M, Vaughan ED Jr, DelPizzo JJ, Scherr DS. Pathologic findings in a modern series of 338 radical and partial nephrectomies for renal mass. Poster at American Urological Association annual meeting, May 2006, Atlanta, GA.
17. Pettus J, Al-Ahmadie H, **Barocas DA**, Koppie TM, Herr H, Donat SM, Dalbagni G, Reuter VE, Donat SM, Olgac S, Bochner B. Risk of surgical undertreatment with prostate-sparing cystectomy. Poster at Society of Urologic Oncology annual meeting, December 2006, Bethesda, MD.
18. **Barocas DA**, Cowan J, Smith JA Jr, Carroll PR. What percentage of patients with newly-diagnosed carcinoma of the prostate are candidates for surveillance? An analysis of the CaPSURE Database. Podium Presentation and Poster at American Society of Clinical Oncologists Prostate Cancer Symposium, February 2007, Orlando, FL.
19. **Barocas DA**, Cowan J, Smith JA Jr, Carroll PR. What percentage of patients with newly-diagnosed carcinoma of the prostate are candidates for surveillance? An analysis of the CaPSURE Database. Poster at American Urological Association annual meeting, May 2007, Anaheim, CA.
20. Tewari A, Mandhani A, Takenaka A, Rao S, Ramanathan R, Martinez-Salamanca J, **Barocas DA**, Berryhill R, Bigelow K, Leung R, Menon M, Bartsch G, Vaughan ED. Deciphering the DaVinci code: Complex tri-zonal neural architecture of erectile nerves and their importance in nerve sparing robotic prostatectomy. Video at American Urological Association annual meeting, May 2007, Anaheim, CA.
21. Wang GJ, **Barocas DA**, Raman JD, Scherr DS. Robotic versus open radical cystectomy: Prospective comparison of perioperative and early pathologic outcomes. Podium presentation at American Urological Association annual meeting, May 2007, Anaheim, CA.

22. **Barocas DA**, Palese M, Kapur S, Sosa RE, DelPizzo JJ. Complications of laparoscopic donor nephrectomy. Podium presentation at American Urological Association annual meeting, May 2007, Anaheim, CA.
23. Wang GJ, **Barocas DA**, Raman JD, Li P, Scherr DS. Prospective comparison of perioperative and early pathologic outcomes between robotic and open radical cystectomy. Society of Laparoendoscopic Surgeons annual meeting, September 2007, San Francisco, CA. *Winner Best Urology Video Award.
24. **Barocas DA**, Chang SS, Clark PE, Patel SG, Smith JA Jr, Cookson MS. Outcomes of patients undergoing radical cystoprostatectomy for bladder cancer with prostatic involvement on final pathology. Poster at Society of Urologic Oncology annual meeting, December 2007, Bethesda, MD.
25. **Barocas DA**, Lea WB, Clark PE, Chang SS, Herrell SD, Smith JA Jr, Cookson, MS. Utilization of systemic therapy in patients undergoing cytoreductive nephrectomy as a component of multi-modal therapy for renal cell carcinoma. Poster at American Society of Clinical Oncologists Genitourinary Symposium, February 2008, San Francisco, CA.
26. **Barocas DA**, Chang SS, Clark PE, Patel SG, Smith JA Jr, Cookson MS. Outcomes of patients undergoing radical cystoprostatectomy for bladder cancer with prostatic involvement on final pathology. Poster at American Society of Clinical Oncologists Genitourinary Symposium, February 2008, San Francisco, CA.
27. Chan RC, **Barocas DA**, Cookson MS, Herrell SD, Clark PE, Baumgartner R, Smith JA Jr, Chang SS. Prostate volume and high grade prostate cancer in robotic and open retropubic radical prostatectomy. Poster at the Annual Meeting of the Southeastern Section of the American Urological Association, March 2008, San Diego, CA.
28. Chan RC, **Barocas DA**, Chang SS, Herrell SD, Clark PE, Baumgartner R, Smith JA Jr, Cookson MS. Robotic-assisted versus open radical retropubic prostatectomy in obese and non-obese patients. Poster at the Annual Meeting of the Southeastern Section of the American Urological Association, March 2008, San Diego, CA.
29. Patel SG, Chang SS, **Barocas DA**, Clark PE, Smith JA Jr, Cookson MS. Outcomes of patients undergoing radical cystoprostatectomy for bladder cancer with prostatic involvement on final pathology. Poster at the Southeastern Section of the American Urological Association annual meeting, March 2008, San Diego, CA.
30. Kauffman EC, Ng CK, Wang GJ, Wysock JS, **Barocas DA**, Raman JD, Scherr DS. Experience with robotic-assisted laparoscopic radical cystectomy: Perioperative and short-term oncologic outcomes. Poster at the American Urological Association annual meeting, May 2008, Orlando FL. *Best Poster Award.
31. Wang GH, Ng CK, **Barocas DA**, Raman JD, Li PS, Scherr DS. Robotic versus open radical cystectomy: Prospective comparison of perioperative outcomes and pathologic measures of

- early oncologic efficacy. Video at the American Urological Association annual meeting, May 2008, Orlando FL.
32. Patel SG, Cookson MS, Clark PE, **Barocas DA**, Smith JA Jr, Chang SS. Risk factors for urothelial carcinoma of the prostate in patients undergoing radical cystoprostatectomy for bladder cancer. Podium presentation at the American Urological Association annual meeting, May 2008, Orlando FL.
 33. Boudreaux KJ, Chang SS, Lowrance WT, Rumohr JA, **Barocas DA**, Cookson MS, Smith JA Jr. A comparison of American Joint Committee on Cancer pathologic stage T3a versus T3b urothelial cancer: Analysis of patient outcomes. Poster at the American Urological Association annual meeting, May 2008, Orlando FL.
 34. Boudreaux KJ, Chang SS, Lowrance WT, Rumohr JA, **Barocas DA**, Cookson MS, Smith JA Jr. A comparison of American Joint Committee on Cancer pathologic stage T2a versus T2b urothelial cancer: Analysis of patient outcomes in organ confined bladder cancer. Poster at the American Urological Association annual meeting, May 2008, Orlando FL.
 35. Kauffman EC, **Barocas DA**, Yang SJ, Liu H, Scherr DS, Tu JJ. KAI1 is a novel biomarker for chromophobe renal cell carcinoma. Poster at the American Urological Association annual meeting, May 2008, Orlando FL. *Best Poster Award.
 36. Mitchell RE, Lee BT, Cookson MS, **Barocas DA**, Herrell SD, Clark PE, Smith JA Jr, Chang SS. Immediate surgical outcomes for radical prostatectomy in the University Health System Consortium Database: The impact of hospital case volume, hospital size, and geographic region on 48,000 patients. Poster at the American Urological Association annual meeting, May 2008, Orlando FL.
 37. Mitchell RE, Lee BT, Cookson MS, **Barocas DA**, Herrell SD, Clark PE, Smith JA Jr, Chang SS. Radical nephrectomy surgical outcomes in the University Health System Consortium Database: The impact of hospital case volume, hospital size, and geographic location on 40,000 patients. Poster at the American Urological Association annual meeting, May 2008, Orlando FL.
 38. **Barocas DA**, Lea WB, Clark PE, Chang SS, Herrell SD, Smith JA Jr, Cookson MS. Utilization of systemic therapy in patients undergoing cytoreductive nephrectomy as a component of multi-modal therapy for renal cell carcinoma. Poster at the American Urological Association annual meeting, May 2008, Orlando FL.
 39. **Barocas DA**, Lea WB, Clark PE, Chang SS, Herrell SD, Smith JA Jr, Cookson MS. Survival outcomes in patients undergoing cytoreductive nephrectomy as a component of multi-modal therapy for renal cell carcinoma. Poster at the American Urological Association annual meeting, May 2008, Orlando FL.
 40. **Barocas DA**, Chang SS, Mishra V, Chan RC, Herrell SD, Clark PE, Baumgartner R, Smith JA Jr, Cookson MS. Comparison of transfusion requirements between open and robotic assisted laparoscopic radical prostatectomy. Podium presentation at the Southeastern Section of the American Urological Association, March 2009, Mobile, AL.

41. Humphrey JE, Stimson CJ, Chang SS, Clark PE, **Barocas DA**, Patel SG, Smith JA Jr, Cookson MS. Analysis of hospital readmission rates within 90 days following cystectomy. Podium presentation at the Southeastern Section of the American Urological Association, March 2009, Mobile, AL.
42. Humphrey JE, Stimson CJ, Chang SS, Clark PE, **Barocas DA**, Patel SG, Smith JA Jr, Cookson MS. Pre-operative hydronephrosis predicts extravesical and node positive disease prior to cystectomy. Podium presentation at the Southeastern Section of the American Urological Association, March 2009, Mobile, AL.
43. Stimson CJ, Humphrey JE, Patel SG, Clark PE, **Barocas DA**, Chang SS, Smith JA Jr, Cookson MS. Analysis of early and late hospital readmissions following radical cystectomy. Poster at the American Urological Association annual meeting, April 2009, Chicago, IL.
44. **Barocas DA**, Salem Shady, Kordan Y, Herrell SD, Chang SS, Clark PE, Davis R, Phillips S, Cookson MS, Smith JA Jr. Comparison of 3-year cancer control outcomes in robotic-assisted laparoscopic prostatectomy (RALP) versus radical retropubic prostatectomy (RRP) for prostate cancer. Podium presentation at the American Urological Association annual meeting, April 2009, Chicago, IL.
45. Kordan Y, Salem S, Chang SS, Clark PE, Cookson MS, Davis R, Herrell SD, Phillips S, Baumgartner R, Smith JA Jr, **Barocas DA**. Impact of positive apical surgical margins on the likelihood of biochemical recurrence after prostatectomy. Poster at the American Urological Association annual meeting, April 2009, Chicago, IL.
46. Newton MR, Cookson MS, Chan R, Chang SS, Clark PE, Davis R, Herrell SD, Mishra V, Phillips S, Smith JA Jr, **Barocas DA**. Relationship between prostate volume and pathologic grade of prostate cancer. Poster at the American Urological Association annual meeting, April 2009, Chicago, IL.
47. Kaufman MR, Dietrich MS, Clark PE, **Barocas DA**, Chang SS, Davis R, Cookson MS, Smith JA Jr, Herrell SD. Identification of distinct outcomes clusters for urinary function following radical prostatectomy. Poster at the American Urological Association annual meeting, April 2009, Chicago, IL.
48. Kaufman MR, Dietrich MS, Clark PE, **Barocas DA**, Chang SS, Davis R, Cookson MS, Smith JA Jr, Herrell SD. Relationship of urinary function following radical prostatectomy with medical comorbidities and global quality of life parameters. Poster at the American Urological Association annual meeting, April 2009, Chicago, IL.
49. **Barocas DA**, Patel SG, Chang SS, Clark PE, Smith JA Jr, Cookson MS. Urothelial carcinoma of the bladder with mixed histology: Is this a bad actor? Poster at the Southeastern Section of the American Urological Association, March 2009, Mobile, AL.
50. **Barocas DA**, Patel SG, Cookson MS, Welty CJ, Clark PE, Smith JA Jr, Chang SS. Smoking cessation in patients undergoing radical cystectomy for bladder cancer. Podium

- presentation at the Southeastern Section of the American Urological Association, March 2009, Mobile, AL.
51. Stratton K, Hutchinson R, Chang SS, Stec A, Coons B, Cookson MS, Herrell SD, **Barocas DA**, Smith JA Jr, Clark PE. Necrosis as a predictor of survival following nephrectomy for pathologic T2 renal cell carcinoma. Podium presentation at the Southeastern Section of the American Urological Association, March 2010, Miami, FL.
 52. Stratton K, Lightfoot M, Chang SS, Stec A, Coons B, Cookson MS, Herrell SD, **Barocas DA**, Smith JA Jr, Clark PE. Effect of preoperative hypercalcemia on survival following nephrectomy for pathologic T1 renal cell carcinoma. Podium presentation at the Southeastern Section of the American Urological Association, March 2010, Miami, FL.
 53. Gregg JR, Salem S, Chang SS, Clark PE, Cookson MS, Davis R, Stimson CJ, Aghazadeh M, Smith JA Jr, **Barocas DA**. Effects of pre-operative nutritional deficiency on 90-day mortality and overall survival in patients undergoing radical cystectomy for bladder cancer. Podium presentation at the Southeastern Section of the American Urological Association, March 2010, Miami, FL.
 54. Morgan TM, **Barocas DA**, Chang SS, Clark PE, Salem S, Smith JA Jr, Cookson MS. Perioperative blood transfusion increases the risk of overall mortality in patients undergoing radical cystectomy for bladder cancer. Podium presentation at the Southeastern Section of the American Urological Association, March 2010, Miami, FL.
 55. Stimson DJ, Humphrey JE, Cookson MS, Clark PE, **Barocas DA**, Smith JA Jr, Chang SS. The inaccuracy of computed tomography in preoperative staging of radical cystectomy patients. Podium presentation at the Southeastern Section of the American Urological Association, March 2010, Miami, FL.
 56. Patel SG, **Barocas DA**, Cookson MS, Clark PE, Penson DF, Smith JA Jr, Chang SS. Assessment of the 2002 AJCC nodal staging of bladder urothelial carcinoma. Podium presentation at the Southeastern Section of the American Urological Association, March 2010, Miami, FL.
 57. Salem S, Chang SS, Cookson MS, Davis R, Baumgartner, Clark PE, Smith JA Jr, **Barocas DA**. Blood loss and transfusion with robotic assisted radical cystectomy (RARC) versus open radical cystectomy (ORC) for bladder cancer. Podium presentation at the Southeastern Section of the American Urological Association, March 2010, Miami, FL.
 58. Aghazadeh MA, **Barocas DA**, Salem S, Clark PE, Cookson MS, Davis R, Gregg J, Stimson CJ, Smith JA Jr, Chang SS. Discharge status after radical cystectomy: What determines where our patients go? Podium presentation at the Southeastern Section of the American Urological Association, March 2010, Miami, FL.
 59. Patel SG, **Barocas DA**, Cookson MS, Clark PE, Penson DF, Smith JA Jr, Chang SS. Assessment of the 2002 AJCC nodal staging of bladder urothelial carcinoma. Poster at the American Urological Association annual meeting, May 2010, San Francisco, CA.

60. Gregg JR, Salem S, Chang SS, Clark PE, Cookson MS, Davis R, Stimson CJ, Aghazadeh M, Smith JA Jr, **Barocas DA**. Effects of pre-operative nutritional deficiency on 90-day mortality and overall survival in patients undergoing radical cystectomy for bladder cancer. Poster at the American Urological Association annual meeting, May 2010, San Francisco, CA.
61. Morgan TM, **Barocas DA**, Chang SS, Clark PE, Salem S, Smith JA Jr, Cookson MS. Perioperative blood transfusion increases the risk of overall mortality in patients undergoing radical cystectomy for bladder cancer. Poster at the American Urological Association annual meeting, May 2010, San Francisco, CA.
62. **Barocas DA**, Motley S, Dai Q, Milne G, Morrow J, Cookson MS, Smith JA Jr, Fowke JH. The association between oxidative stress and prostate cancer risk in men undergoing prostate biopsy. Poster at the American Urological Association annual meeting, May 2010, San Francisco, CA.
63. **Barocas DA**, Gray D, Penson DF, Fowke JH, Chang SS, Cookson MS, Phillips S, Smith JA Jr. Racial variation in the utilization of high-volume surgeons and high-volume hospitals for radical prostatectomy among men with prostate cancer. Poster at the American College of Surgeons annual meeting, October 2010, Washington, DC.
64. Morgan TM, Keegan KA, Ruhotina N, Chang SS, **Barocas DA**, Penson DF, Clark PE, Smith JA Jr, Cookson MS. Predicting the probability of 90-day survival in elderly bladder cancer patients treated with radical cystectomy. Young Urologic Oncologist Featured Podium at the Society of Urologic Oncology annual meeting, December 2010, Bethesda, MD.
65. Thompson III, IM, Salem S, Chang SS, Clark PE, Davis R, Herrell SD, Kordan Y, Baumgartner R, Phillips S, Smith, Jr. JA, Cookson MS, **Barocas DA**. Tumor volume as a predictor of adverse pathologic features and biochemical recurrence in radical prostatectomy specimens; a tale of two methods. Poster at the Society of Urologic Oncology annual meeting, December 2010, Bethesda, MD.
66. Morgan TM, Tang D, **Barocas DA**, Anderson CB, Stratton KL, Chang SS, Cookson MS, Smith JA Jr, Clark PE. Pre-operative nutritional status is an important predictor of survival following surgery for renal cell carcinoma. Poster at the Society of Urologic Oncology annual meeting, December 2010, Bethesda, MD.
67. Davies J, Aghazadeh M, Phillips S, Salem S, Clark PE, Cookson MS, Davis R, Herrell SD, Chang SS, Smith JA Jr, **Barocas DA**. Prostate size as a predictor of Gleason score upgrading in low-risk prostate cancer patients. Poster at the Society of Urologic Oncology annual meeting, December 2010, Bethesda, MD.
68. Aghazadeh MA, **Barocas DA**, Salem S, Clark PE, Cookson MS, Davis R, Gregg J, Stimson CJ, Smith JA Jr, Chang SS. Discharge status after radical cystectomy: What determines where our patients go? Podium presentation at the Southeastern Section of the American Urological Association, March 2010, Miami, FL.

69. **Barocas DA**, Gray D, Penson DF, Fowke JH, Kappa S, Blume J, Phillips S, Chang SS, Cookson MS, Smith JA Jr. Racial variation in the utilization of high-volume surgeons and high-volume hospitals for radical prostatectomy among men with prostate cancer. Poster at the Society of Urologic Oncology annual meeting, December 2010, Bethesda, MD.
70. Gregg JR, Salem S, Chang SS, Clark PE, Cookson MS, Davis R, Stimson, III, CJ, Aghazadeh MA, Smith JA Jr, **Barocas DA**. Effects of pre-operative nutritional deficiency on 90-day mortality and overall survival in patients undergoing radical cystectomy for bladder cancer. Poster at the Society of Urologic Oncology annual meeting, December 2010, Bethesda, MD.
71. Tang D, Morgan TM, **Barocas DA**, Anderson CB, Stratton KL, Herrell SD, Chang SS, Cookson MS, Smith JA Jr, Clark PE. Pre-operative nutritional status is associated with survival after nephrectomy for renal cell carcinoma. Podium presentation at the Southeastern Section of the American Urological Association annual meeting, March 2011, New Orleans, LA.
72. Adekoya E, Mitchell RM III, Penson DF, Fowke JH, **Barocas DA**. The influence of socio-demographic factors, race, ethnicity, and the doctor-patient relationship on PSA screening behavior. Poster at the Southeastern Section of the American Urological Association annual meeting, March 2011, New Orleans, LA.
73. Thompson IM III, Salem S, Chang SS, Clark PE, Davis R, Herrell SD, Kordan Y, Baumgartner R, Phillips S, Smith JA Jr, Cookson MS, **Barocas DA**. Tumor volume as a predictor of adverse pathologic features and biochemical recurrence in radical prostatectomy specimens: A tale of two methods. Poster at the Southeastern Section of the American Urological Association annual meeting, March 2011, New Orleans, LA.
74. Ruhotina N, Morgan TM, Chang SS, **Barocas DA**, Keegan KA, Penson DF, Clark PE, Smith JA Jr, Cookson MS. Predicting the probability of 90-day survival in elderly bladder cancer patients treated with radical cystectomy. Podium presentation at the Southeastern Section of the American Urological Association annual meeting, March 2011, New Orleans, LA.
75. Morgan TM, Stratton KL, Cookson MS, **Barocas DA**, Davis R, Herrell SD, Smith JA Jr, Chang SS, Clark PE. Perioperative blood transfusion and survival in patients undergoing nephrectomy for renal cell carcinoma. Poster at the Southeastern Section of the American Urological Association annual meeting, March 2011, New Orleans, LA.
76. **Barocas DA**, Gray D, Fowke JH, Kappa S, Blume J, Mercaldo N, Chang SS, Cookson MS, Smith JA Jr., Penson DF. Racial variation in the utilization of high-volume surgeons and hospitals for radical prostatectomy. Poster at the American Urological Association annual meeting, May 2011, Washington, DC.
77. **Barocas DA**, Gray D, Fowke JH, Chang SS, Cookson MS, Smith JA Jr, Penson DF. Racial variation in the quality of care among patients undergoing cystectomy for bladder cancer. Podium presentation at the American Urological Association annual meeting, May 2011, Washington, DC.

78. Penson DF, **Barocas DA**, Van Horn RL. Regional variation in prostate cancer treatment is not consistent across age groups. Poster at the American Urological Association annual meeting, May 2011, Washington, DC.
79. Morgan TM, Tang D, Stratton KL, **Barocas DA**, Anderson CB, Gregg JR, Chang SS, Cookson MS, Herrell SD, Smith JA Jr, Clark PE. Pre-operative nutritional status is an important predictor of survival following surgery for renal cell carcinoma. Poster at the American Urological Association annual meeting, May 2011, Washington, DC.
80. Kappa SF, Salem S, Chang SS, Clark PE, Cookson MS, Davis R, Penson DF, Baumgartner R, You C, Smith JA Jr, **Barocas DA**. Use of robotic assisted radical cystectomy versus open radical cystectomy for bladder cancer is associated with lower blood loss and perioperative transfusion rate. Poster at the American Urological Association annual meeting, May 2011, Washington, DC.
81. Morgan TM, Ruhotina N, Keegan KA, **Barocas DA**, Chang SS, Penson DF, Clark PE, Smith JA Jr, Cookson MS. Predicting the probability of 90-day survival in elderly bladder cancer patients treated with radical cystectomy. Poster at the American Urological Association annual meeting, May 2011, Washington, DC.
82. Davies JD, Simons CM, Ruhotina N, **Barocas DA**, Clark PE, Morgan TM. Pelvic lymph node dissection for bladder cancer: an autopsy study. Poster at the American Urological Association annual meeting, May 2011, Washington, DC.
83. **Barocas DA**, Gray D, Fowke JH, Chang S, Cookson MS, Smith JA Jr, Penson DF. Racial variation in the quality of care among patients undergoing cystectomy for bladder cancer. Podium presentation at the American College of Surgeons annual Clinical Congress, October 2011, San Francisco, CA.
84. Thompson IM III, **Barocas DA**, Bischoff CJ, Clark PE, Cookson MS, Kappa SF, Morgan TM, Resnick MJ, Smith JA Jr, Chang SS. Blood loss associated with radical cystectomy: A prospective randomized study comparing impact LigaSure versus stapling device. Poster at the Society of Urologic Oncology annual meeting, November 2011, Bethesda, MD.
85. Patel SG, Patel V, Keegan KA, **Barocas DA**, Penson DF, Cookson MS, Chang SS, Clark PE, Smith JA Jr, Morgan TM. A comparative analysis of oncologic outcomes in patients with variant histology bladder cancer. Poster at the Society of Urologic Oncology annual meeting, November 2011, Bethesda, MD.
86. Anderson CB, Feurer ID, Large M, Steinberg G, **Barocas DA**, Cookson MS, Penson DF. Psychometric characteristics of a condition-specific health-related quality of life survey: The FACT-vanderbilt cystectomy index. Poster at the Society of Urologic Oncology annual meeting, November 2011, Bethesda, MD.
87. Morgan TM, **Barocas DA**, Keegan KA, Cookson MS, Chang SS, Clark PE, Ni S, Smith JA Jr, Penson DF. Volume-outcomes in cystectomy: Is it the surgeon or the setting? Poster at the Society of Urologic Oncology annual meeting, November 2011, Bethesda, MD.

88. Patel SG, Patel V, Keegan KA, **Barocas DA**, Penson DF, Cookson MS, Chang SS, Clark PE, Smith JA Jr, Morgan TM. Treatment patterns and survival outcomes of patients 50 Years old and younger undergoing definitive treatment for bladder urothelial cell carcinoma. Poster at the Society of Urologic Oncology annual meeting, November 2011, Bethesda, MD.
89. Kappa SF, Morgan TM, Baumgartner RG, Chang SS, Cookson MS, Clark PE, Davis R, Penson DF, Smith JA Jr, You C, **Barocas DA**. Use of pelvic lymphadenectomy in radical cystectomy for bladder cancer: 10-year experience at a single institution. Poster at the Society of Urologic Oncology annual meeting, November 2011, Bethesda, MD.
90. Kaffenberger SD, Morgan TM, Stratton K, Boachie A, **Barocas DA**, Chang SS, Cookson MS, Herrell SD, Smith JA Jr, Clark PE. ABO blood type is an independent predictor of overall survival in patients with renal cell carcinoma. Poster at the Society of Urologic Oncology annual meeting, November 2011, Bethesda, MD.
91. Anderson CB, Pyle A, Woodworth A, Cookson MS, Smith JA Jr, **Barocas DA**. Spurious elevation of serum prostate-specific antigen after curative treatment for prostate cancer: clinical consequences and the role of heterophilic antibodies. Poster at the Society of Urologic Oncology annual meeting, November 2011, Bethesda, MD.
92. Kaffenberger SD, Keegan KA, Morgan TM, Tang DH, Bansal NK, **Barocas DA**, Penson DF, Davis R, Clark PE, Chang SS, Cookson MS, Herrell SD, Smith JA Jr. Salvage robotic-assisted laparoscopic radical prostatectomy: A single institution five-year experience. Poster at the Society of Urologic Oncology annual meeting, November 2011, Bethesda, MD.
93. **Barocas DA**, Gallagher J, Colayco D, Schwartz B, Heap K, Globe D. Utilization of immediate postoperative instillation of intravesical chemotherapy (IPOIC): A quality of care concern in older patients with non-muscle invasive bladder cancer (NMIBC). Poster at the Society of Urologic Oncology annual meeting, November 2011, Bethesda, MD.
94. Kappa SF, Morgan TM, Baumgartner RG, Chang SS, Cookson MS, Clark PE, Davis R, Penson DF, Smith JA Jr, You C, **Barocas DA**. Use of neoadjuvant chemotherapy for muscle-invasive bladder cancer: 10-year experience at a single institution. Poster at the Society of Urologic Oncology annual meeting, November 2011, Bethesda, MD.
95. Kaffenberger SD, Morgan TM, Tang DH, Ark JT, **Barocas DA**, Chang SS, Cookson MS, Herrell SD, Smith JA Jr, Clark PE. A prognostic model for survival following cytoreductive nephrectomy for metastatic renal cell carcinoma. Poster at the Society of Urologic Oncology annual meeting, November 2011, Bethesda, MD.
96. Anderson CB, Ni S, Penson DF, **Barocas DA**. Trends in usage of radical prostatectomy in the United States: 2000-2008. Poster at the Society of Urologic Oncology annual meeting, November 2011, Bethesda, MD.

97. Anderson CB, Kaufman MR, Dietrich M, **Barocas DA**, Chang SS, Cookson MS, Smith JA Jr, Clark PE, Herrell SD. Recovery of urinary function following radical prostatectomy: Identification of trajectory cluster groups. Poster at the Society of Urologic Oncology annual meeting, November 2011, Bethesda, MD.
98. Morgan TM, **Barocas DA**, Keegan KA, Cookson MS, Chang SS, Clark PE, Ni S, Smith JA Jr, Penson DF. Volume-outcomes in cystectomy: Is it the surgeon or the setting? Podium presentation at the Southeastern Section of the American Urological Association annual meeting, March 2012, Amelia Island, FL.
99. Thompson IM III, **Barocas DA**, Bischoff CJ, Clark PE, Cookson MS, Kappa SF, Morgan TM, Resnick MJ, Smith JA Jr, Chang SS. Blood loss associated with radical cystectomy: A prospective randomized study comparing impact LigaSure versus stapling device. Podium presentation at the Southeastern Section of the American Urological Association annual meeting, March 2012, Amelia Island, FL.
100. Patel SG, Patel V, Keegan KA, **Barocas DA**, Penson DF, Cookson MS, Chang SS, Clark PE, Smith JA Jr, Morgan TM. A comparative analysis of oncologic outcomes in patients with variant histology bladder cancer. Podium presentation at the Southeastern Section of the American Urological Association annual meeting, March 2012, Amelia Island, FL.
101. Kappa SF, Morgan TM, Baumgartner RG, Chang SS, Cookson MS, Clark PE, Davis R, Penson DF, Smith JA Jr, You C, **Barocas DA**. Neoadjuvant chemotherapy for muscle-invasive bladder cancer: 10-year experience at a single institution. Podium presentation at the Southeastern Section of the American Urological Association annual meeting, March 2012, Amelia Island, FL.
102. Kappa SF, Morgan TM, Baumgartner RG, Chang SS, Cookson MS, Clark PE, Davis R, Penson DF, Smith JA Jr, You C, **Barocas DA**. Use of pelvic lymphadenectomy in radical cystectomy for bladder cancer: 10-year experience at a single institution. Poster at the Southeastern Section of the American Urological Association annual meeting, March 2012, Amelia Island, FL.
103. Kaffenberger SD, Keegan KA, Morgan TM, Tang DH, Bansal NK, **Barocas DA**, Penson DF, Davis R, Clark PE, Chang SS, Cookson MS, Herrell SD, Smith JA Jr. Salvage robotic-assisted laparoscopic radical prostatectomy: A single institution five-year experience. Poster at the Southeastern Section of the American Urological Association annual meeting, March 2012, Amelia Island, FL.
104. Anderson CB, Kaufman MR, Dietrich M, **Barocas DA**, Chang SS, Cookson MS, Smith JA Jr, Clark PE, Herrell SD. Recovery of urinary function following radical prostatectomy: Identification of trajectory cluster groups. Poster at the Southeastern Section of the American Urological Association annual meeting, March 2012, Amelia Island, FL.
105. Kaffenberger SD, Morgan TM, Tang DH, Ark JT, **Barocas DA**, Chang SS, Cookson MS, Herrell SD, Smith JA Jr, Clark PE. A prognostic model for survival following cytoreductive

- nephrectomy for metastatic renal cell carcinoma. Poster at the Southeastern Section of the American Urological Association annual meeting, March 2012, Amelia Island, FL.
106. Ark JT, Keegan KA, Talbot TR, Johnson JG, Chang SS, Clark PE, Cookson MS, Davis R, Penson DF, Smith JA Jr, You C, **Barocas DA**. The rising incidence of fluoroquinolone exposure and subsequent resistance during prophylaxis for transrectal ultrasound-guided prostate biopsy. Poster at the Southeastern Section of the American Urological Association annual meeting, March 2012, Amelia Island, FL.
 107. Kaffenberger SD, Morgan TM, Stratton K, Boachie A, **Barocas DA**, Chang SS, Cookson MS, Herrell SD, Smith JA Jr, Clark PE. ABO blood type is an independent predictor of overall survival in patients with renal cell carcinoma. Podium presentation at the Southeastern Section of the American Urological Association annual meeting, March 2012, Amelia Island, FL.
 108. Patel SG, Penson DF, Pabla BS, Clark PE, Cookson MS, Chang SS, Herrell SD, Smith JA Jr, **Barocas DA**. National trends on the utilization of partial nephrectomy: A rising tide that has not lifted all boats. Podium presentation at the Southeastern Section of the American Urological Association annual meeting, March 2012, Amelia Island, FL.
 109. Thompson IM III, **Barocas DA**, Bischoff CJ, Clark PE, Cookson MS, Kappa SF, Morgan TM, Resnick MJ, Smith JA Jr, Chang SS. Blood loss associated with radical cystectomy: A prospective randomized study comparing impact LigaSure versus stapling device. Poster at the American Urological Association annual meeting, May 2012, Atlanta, GA.
 110. Kappa SF, Morgan TM, Baumgartner RG, Chang SS, Cookson MS, Clark PE, Davis R, Penson DF, Smith JA Jr, You C, **Barocas DA**. Use of pelvic lymphadenectomy in radical cystectomy for bladder cancer: 10-year experience at a single institution. Poster at the American Urological Association annual meeting, May 2012, Atlanta, GA.
 111. Patel SG, Patel V, **Barocas DA**, Cookson MS, Chang SS, Clark PE, Smith JA Jr, Morgan TM. Treatment patterns and survival outcomes of patients 50 Years old and younger undergoing definitive treatment for bladder urothelial cell carcinoma. Poster at the American Urological Association annual meeting, May 2012, Atlanta, GA.
 112. Kaffenberger SD, Morgan TM, Tang DH, Ark JT, **Barocas DA**, Chang SS, Cookson MS, Herrell SD, Smith JA Jr, Clark PE. A prognostic model for survival following cytoreductive nephrectomy for metastatic renal cell carcinoma. Poster at the American Urological Association annual meeting, May 2012, Atlanta, GA.
 113. Ark JT, **Barocas DA**, Keegan KA, Morgan TM, Resnick MJ, You C, Cookson MS, Penson DF, Davis R, Clark PE, Smith JA, Jr., Chang SS. Worth a second look: Rates of upstaging at the time of radical cystectomy after restaging TURBT for persistent T1 urothelial carcinoma. Poster at the American Urological Association annual meeting, May 2012, Atlanta, GA.

114. Morgan TM, **Barocas DA**, Keegan KA, Cookson MS, Chang SS, Clark PE, Ni S, Smith JA Jr, Penson DF. Volume-outcomes in cystectomy: Is it the surgeon or the setting? Podium presentation at the American Urological Association annual meeting, May 2012, Atlanta, GA.
115. Kaffenberger SD, Keegan KA, Morgan TM, Bansal NK, Tang DH, **Barocas DA**, Penson DF, Davis R, Clark PE, Cookson MS, Herrell SD, Smith JA Jr. Salvage robotic-assisted laparoscopic radical prostatectomy: A single institution five-year experience. Podium presentation at the American Urological Association annual meeting, May 2012, Atlanta, GA.
116. Anderson CB, Ni S, Penson DF, **Barocas DA**. National trends in utilization of radical prostatectomy from 2000-2008. Poster at the American Urological Association annual meeting, May 2012, Atlanta, GA.
117. Keegan KA, Morgan, TM, Resnick MJ, Anderson CB, Ni S, Davis R, Cookson MS, Chang SS, Clark PE, Smith JA Jr, Penson DF, **Barocas DA**. Changing utilization of neoadjuvant and adjuvant chemotherapies for muscle-invasive urothelial carcinoma after publication of landmark manuscripts. Podium presentation at the American Urological Association annual meeting, May 2012, Atlanta, GA.
118. Kaffenberger SD, Morgan TM, Stratton K, Boachie A, **Barocas DA**, Chang SS, Cookson MS, Herrell SD, Smith JA Jr, Clark PE. ABO blood type is an independent predictor of overall survival in patients with renal cell carcinoma. Podium presentation at the American Urological Association annual meeting, May 2012, Atlanta, GA.
119. Anderson CB, Kaufman MR, Dietrich M, **Barocas DA**, Chang SS, Cookson MS, Smith JA Jr, Clark PE, Herrell SD. Recovery of urinary function following radical prostatectomy: Identification of trajectory cluster groups. Poster at the American Urological Association annual meeting, May 2012, Atlanta, GA.
120. Kappa SF, Morgan TM, Van Horn RL, Chang SS, Clark PE, Cookson MS, Davis R, Penson DF, Smith JA Jr, You C, **Barocas DA**. Perioperative cost comparison of robotic and open radical cystectomy for bladder cancer. Podium presentation at the American Urological Association annual meeting, May 2012, Atlanta, GA.
121. Broughton GJ, Clark PE, **Barocas DA**, Krajewski P, Davis R, Smith JA Jr, Cookson MS, Herrell SD, Chang SS. Contemporary management of small renal masses: Partial nephrectomy is associated exclusively with tumor anatomic complexity. Poster at the American Urological Association annual meeting, May 2012, Atlanta, GA.
122. Anderson CB, Alvarez J, Koyama T, Penson DF, **Barocas DA**. Women are less likely to receive evidence-based processes of care for the treatment of bladder cancer as compared to men. Poster at the Society of Urologic Oncology annual meeting, December 2012, Bethesda, MD.
123. Moore D, Resnick MJ, **Barocas DA**, Clark PE, Cookson MS, Herrell SD, Kulahalli C, Smith JA Jr., You C, Chang S. Predictors of recurrence in patients with high-risk pathology after prostatectomy. Poster at the Society of Urologic Oncology annual meeting, December 2012, Bethesda, MD.

124. Resnick MJ, Fan K-H, Koyama T, Keegan KA, **Barocas DA**, Albersten P, Penson DF. Long term treatment regret among men treated with radical prostatectomy or external beam radiation therapy for localized prostate cancer: results from the prostate cancer outcomes study. Poster at the Society of Urologic Oncology annual meeting, December 2012, Bethesda, MD.
125. Patel SG, Stimson CJ Jr., Zaid HB, **Barocas DA**, Resnick MJ, Chang SS. Neoadjuvant chemotherapy in muscle-invasive bladder cancer: trends in utilization and implications for pathologic staging in the National Cancer Database. Podium presentation at the Society of Urologic Oncology annual meeting, December 2012, Bethesda, MD.
126. Anderson CB, Morgan TM, Kappa S, Moore D, Clark P, Davis R, Penson DF, **Barocas DA**, Smith JA Jr., Cookson MS, Chang SS. Ureteroenteric anastomotic strictures after radical cystectomy: does operative approach matter? Poster at the Society of Urologic Oncology annual meeting, December 2012, Bethesda, MD.
127. Patel SG, Stimson CJ Jr., Zaid HB, **Barocas DA**, Resnick MJ, Chang SS. Patterns of care for elderly patients with invasive bladder cancer: treatment choices from the National Cancer Database. Poster at the Society of Urologic Oncology annual meeting, December 2012, Bethesda, MD.
128. Patel SG, Stimson CJ Jr., Zaid HB, **Barocas DA**, Resnick MJ, Chang SS. Small cell carcinoma of the bladder: clinical characteristics and treatment patterns. Poster at the Society of Urologic Oncology annual meeting, December 2012, Bethesda, MD.
129. Moore D, Resnick MJ, **Barocas DA**, Clark PE, Cookson MS, Herrell SD, Kulahalli C, Smith JA Jr., You C, Chang S. Predictors of recurrence in patients with high-risk pathology after prostatectomy. Podium presentation at the Southeastern Section of the American Urological Association annual meeting, March 2013, Williamsburg, VA.
130. Patel SG, Stimson CJ Jr., Zaid HB, **Barocas DA**, Resnick MJ, Chang SS. Patterns of care for elderly patients with invasive bladder cancer: treatment choices from the National Cancer Database. Poster at the Southeastern Section of the American Urological Association annual meeting, March 2013, Williamsburg, VA.
131. Anderson CB, Alvarez J, Koyama T, Penson DF, **Barocas DA**. Women are less likely to receive evidence-based processes of care for the treatment of bladder cancer as compared to men. Poster at the Southeastern Section of the American Urological Association annual meeting, March 2013, Williamsburg, VA.
132. Patel SG, Stimson CJ Jr., Zaid HB, **Barocas DA**, Resnick MJ, Chang SS. Neoadjuvant chemotherapy in muscle-invasive bladder cancer: trends in utilization and implications for pathologic staging in the National Cancer Database. Poster at the Southeastern Section of the American Urological Association annual meeting, March 2013, Williamsburg, VA.
133. Patel SG, Stimson CJ Jr., Zaid HB, **Barocas DA**, Resnick MJ, Chang SS. Small cell carcinoma of the bladder: clinical characteristics and treatment patterns. Podium presentation at the

- Southeastern Section of the American Urological Association annual meeting, March 2013, Williamsburg, VA.
134. **Barocas DA**, Montie J, Bradford T, Burks F, Morris D, Murtagh D, Knapp P, Schuster T, Suh R, Dunn R, Liu A, Miller D. Practice-based collaboration to improve the use of immediate intravesical chemotherapy (IVC) for non-muscle-invasive bladder cancer. Podium presentation at the American Urological Association annual meeting, May 2013, San Diego, CA.
 135. **Barocas DA**, Resnick MJ, Morgans MK, Phillips S, Chen V, Cooperberg M, Graff J, Greenfield S, Hamilton A, Hoffman K, Kaplan S, Koyama T, Stroup A, Wu X-C, Penson DF. Association between race and participatory decision making (PDM) in treatment decisions for prostate cancer (PC) management. Podium presentation at the American Urological Association annual meeting, May 2013, San Diego, CA.
 136. **Barocas DA**, Kulahalli C, Penson DF, Weavind L, Kapu A, Dmochowski R. Bench-marking the use of a rapid response team by surgical services at a tertiary care hospital. Podium presentation at the American Urological Association annual meeting, May 2013, San Diego, CA.
 137. Morgans MK, **Barocas DA**, Resnick MJ, Fan K-H, Koyama T, Hoffman K, Kaplan S, Stroop A, Greenfield S, Hamilton A, Chen V, Wu X-C, Hoffman R, Penson DF. Influence of Race and Comorbidity on Therapy for Prostate Cancer: Evolution Over 15 Years. Podium presentation at the American Urological Association annual meeting, May 2013, San Diego, CA.
 138. Resnick MJ, **Barocas DA**, Morgans MK, Phillips S, Chen V, Cooperberg M, Graff J, Greenfield S, Hamilton A, Hoffman K, Kaplan S, Koyama T, Stroup A, Wu X-C, Penson DF. Pre-treatment disease-specific health-related quality of life in a contemporary prostate cancer cohort: results from CEASAR. Podium presentation at the American Urological Association annual meeting, May 2013, San Diego, CA.
 139. Resnick MR, Fan K-H, Koyama T, Keegan KA, **Barocas DA**, Morgans MK, Hamilton A, Stroup A, Albertsen P, Hoffman R, Penson DF. Long term treatment regret among men treated with radical prostatectomy or external beam radiation therapy for localized prostate cancer: results from the Prostate Cancer Outcomes Study. Podium presentation at the American Urological Association annual meeting, May 2013, San Diego, CA.
 140. Resnick MJ, **Barocas DA**, Morgans MK, Phillips S, Fan K-H, Koyama T, Albertsen P, Chen V, Cooperberg M, Graff J, Greenfield S, Hamilton A, Hoffman K, Hoffman R, Kaplan S, Stanford J, Stroup A, Wu X-C, Penson DF. The burden of pre-treatment urinary, sexual, and bowel dysfunction across two decades of prostate cancer: results from PCOS and CEASAR. Podium presentation at the American Urological Association annual meeting, May 2013, San Diego, CA.
 141. **Barocas DA**, Montie J, Bradford T, Burks F, Morris D, Murtagh D, Knapp P, Schuster T, Suh R, Dunn R, Liu A, Miller D. Practice-based collaboration to improve the use of immediate intravesical chemotherapy (IVC) for non-muscle-invasive bladder cancer. Podium

- presentation at the American Urological Association annual meeting, May 2013, San Diego, CA.
142. **Barocas DA**, Resnick MJ, Morgans MK, Phillips S, Chen V, Cooperberg M, Graff J, Greenfield S, Hamilton A, Hoffman K, Kaplan S, Koyama T, Stroup A, Wu X-C, Penson DF. Association between race and participatory decision making (PDM) in treatment decisions for prostate cancer (PC) management. Podium presentation at the American Urological Association annual meeting, May 2013, San Diego, CA.
 143. **Barocas DA**, Kulahalli C, Penson DF, Weavind L, Kapu A, Dmochowski R. Bench-marking the use of a rapid response team by surgical services at a tertiary care hospital. Podium presentation at the American Urological Association annual meeting, May 2013, San Diego, CA.
 144. Morgans MK, **Barocas DA**, Resnick MJ, Fan K-H, Koyama T, Hoffman K, Kaplan S, Stroop A, Greenfield S, Hamilton A, Chen V, Wu X-C, Hoffman R, Penson DF. Influence of Race and Comorbidity on Therapy for Prostate Cancer: Evolution Over 15 Years. Podium presentation at the American Urological Association annual meeting, May 2013, San Diego, CA.
 145. Lin-Tsai O, Kaffenberger S, Stratton K, **Barocas DA**, Chang SS, Cookson MS, Herrell SD, Smith JA Jr., Clark PE. Statin use is associated with improved survival in patients undergoing surgery for renal cell carcinoma. Poster at the American Urological Association annual meeting, May 2013, San Diego, CA.
 146. Kaffenberger S, Lu P, Morgan TM, Koyama T, Tang D, Ark J, **Barocas DA**, Chang SS, Cookson MS, Herrell SD, Clark PE. An updated model and nomogram for survival following cytoreductive nephrectomy for metastatic renal cell carcinoma. Poster at the American Urological Association annual meeting, May 2013, San Diego, CA.
 147. Anderson CB, Alvarez J, Koyama T, Penson DF, **Barocas DA**. Women are less likely to receive evidence-based processes of care for the treatment of bladder cancer as compared to men. Poster at the American Urological Association annual meeting, May 2013, San Diego, CA.
 148. Resnick MJ, **Barocas DA**, Morgans AK, Phillips SE, Chen V, Cooperberg MR, Graff JJ, Greenfield S, Hamilton AS, Hoffman KH, Kaplan SH, Koyama T, Stroup AM, Wu X-C, and Penson DF. Pre-treatment Disease-Specific Health-Related Quality of Life in a Contemporary Prostate Cancer Cohort: Results from CEASAR. Poster at the American College of Surgeons Clinical Congress, October 2013, Washington, DC.
 149. Friedlander DF, Resnick MJ, You C, Bassett J, Yarlagadda V, Penson DF, **Barocas DA**. Variation in the intensity of hematuria evaluation: a target for primary care quality improvement. Podium presentation at the American College of Surgeons Clinical Congress, October 2013, Washington, DC.
 150. **Barocas DA**, Kulahalli DS, Ehrenfeld JM, Kapu AN, Penson DF, You C, Weavind L, Dmochowski RR. Bench-marking the use of a rapid response team by surgical services at a tertiary care hospital. Podium presentation at the American College of Surgeons Clinical Congress, October 2013, Washington, DC.

151. Zaid H, Ritch C, Sun D, Keegan KA, Ark J, Dmochowski RR, Penson DF, Chang SS, **Barocas DA** Cookson MS. Institutional modification of antibiotic prophylaxis protocol reduces infectious complications following transrectal ultrasound guided prostate biopsy. Poster at the Society of Urologic Oncology annual meeting, December 2013, Bethesda, MD.
152. Zaid H, Stimson CW, Kaffenberger S, Patel S, Reardon Z, **Barocas DA**, Resnick MJ, Chang SS. Presentation, evaluation and treatment of leydig cell and sertoli cell testicular cancer: an analysis of 192 patients from the National Cancer Database. Poster at the Society of Urologic Oncology annual meeting, December 2013, Bethesda, MD.
153. Reardon Z, Patel S, Zaid H, Stimson CW, **Barocas DA**, Resnick MJ, Chang SS, and Cookson MS. Increasing use of perioperative chemotherapy in patients undergoing radical cystectomy for invasive bladder cancer. Poster at the Society of Urologic Oncology annual meeting, December 2013, Bethesda, MD.
154. Reardon Z, Zaid H, Stimson CW, Patel S, Kaffenberger S, **Barocas DA**, Resnick MJ, and Chang SS. The influence of access to care on adherence to clinical practice guidelines for testis cancer. Poster at the Society of Urologic Oncology annual meeting, December 2013, Bethesda, MD.
155. Zaid H, Stimson CW, Kaffenberger S, Patel S, Reardon Z, **Barocas DA**, Resnick MJ, Chang SS. Presentation, evaluation and treatment of leydig cell and sertoli cell testicular cancer: an analysis of 192 patients from the National Cancer Database. Poster at the Southeastern Section of the American Urological Association annual meeting, March 2014, Hollywood, FL.
156. Joshi SS, Sun D, Clark PE, **Barocas DA**, Resnick MJ, Cookson MS, Smith Jr. JA, Chang SS. Surveillance imaging after T1 RCC: an over-utilization or necessary care? Poster at the Southeastern Section of the American Urological Association annual meeting, March 2014, Hollywood, FL.
157. Eifler JB, Yarlagadda V, **Barocas DA**, Penson DF, Smith Jr. JA, Chang SS, and Cookson MS. Predicting pathologic upgrading during active surveillance among men with Gleason 6 prostate cancer; Can initial biopsy data allow risk stratification? Poster at the Southeastern Section of the American Urological Association annual meeting, March 2014, Hollywood, FL.
158. Zaid H, Ritch C, Sun D, Keegan KA, Ark J, Dmochowski RR, Penson DF, Chang SS, **Barocas DA** Cookson MS. Institutional modification of antibiotic prophylaxis protocol reduces infectious complications following transrectal ultrasound guided prostate biopsy. Poster at the Southeastern Section of the American Urological Association annual meeting, March 2014, Hollywood, FL.
159. Reardon Z, Zaid H, Stimson CW, Patel S, Kaffenberger S, **Barocas DA**, Resnick MJ, and Chang SS. The influence of access to care on adherence to clinical practice guidelines for testis cancer. Poster at the Southeastern Section of the American Urological Association annual meeting, March 2014, Hollywood, FL.

160. Reardon Z, Patel S, Zaid H, Stimson CW, **Barocas DA**, Resnick MJ, Chang SS, and Cookson MS. Increasing use of perioperative chemotherapy in patients undergoing radical cystectomy for invasive bladder cancer. Poster at the Southeastern Section of the American Urological Association annual meeting, March 2014, Hollywood, FL.
161. Scarpato KR, Kappa SF, Goggins KM, Chang SS, Smith JA Jr, Clark PE, Penson DF, Resnick MJ, **Barocas DA**, Kripalani S, Moses KA. #34 Impact of Health Literacy on Surgical Outcomes Following Radical Cystectomy. Southeastern Section of the American Urological Association Meeting, Nashville, TN, March 18, 2016.
162. Gregg J, Lang M, Chang SS, Clark PE, Cookson, MS, Herrell SD, Penson DF, Resnick MJ, Smith JA Jr, **Barocas DA**. Poster #121 Determining Prostate Cancer Risk Strata Using Only Gleason Score and PSA. Southeastern Section of the AUA, Nashville, TN, March 18, 2016.
163. Kappa SF, Scarpato KR, Goggins KM, Chang SS, Smith JA Jr, Clark PE, Penson DF, Resnick MJ, **Barocas DA**, Kripalani S, Moses KA. Poster #123 Impact of Health Literacy on Discharge Disposition Following Radical Cystectomy. Southeastern Section of the AUA, Nashville, TN, March 18, 2016.